IL-15 based molecules and methods and uses thereof
Through the combination therapy of antibodies and ALT-803, the IL-15N72D:IL-15RαSu/Fc complex is used to enhance the immune response, solving the problem of insufficient immune response to cancer and infection in the prior art, and achieving stronger immune killing capabilities and longer survival time.
Patent Information
- Application Number
- CN202110724454.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2014-06-30
- Filing Date
- 2015-06-30
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2035-06-30
AI Technical Summary
The prior art is difficult to effectively enhance the immune response to cancer and infection, especially in various types of cancer and viral infections, and it is difficult to prevent the recurrence of the disease.
Using a combination therapy of antibodies and ALT-803, an interleukin-15 (IL-15) superstimulant mutant and dimer IL-15 receptor α/Fc fusion protein, which enhances the cells of immune cells. Toxicity and activity, specifically including the use of the combined administration of the IL-15N72D:IL-15RαSu/Fc complex (ALT-803) with antibodies, stimulates the immune response to enhance the ability to fight cancer and infection.
It significantly enhances the immune response ability to a variety of cancers and infections, improves the killing ability of immune cells, prolongs the survival time of patients, and reduces the risk of recurrence of the disease.
Smart Images

Figure CN113384686B_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number "201580046144.3", application date "June 30, 2015", and invention name "IL-15-based molecules, methods and uses thereof". Technical Field
[0002] The present invention generally relates to the field of therapeutics for treating cancer and pathogens. Background Art
[0003] Prior to the invention disclosed herein, there was a great need to develop new strategies to amplify and / or direct immune activity against cancer and infected cells. Summary of the invention
[0004] The present invention is based, at least in part, on the surprising discovery that combinations of antibodies and ALT-803, a complex of an interleukin-15 (IL-15) hyperactive mutant and a dimeric IL-15 receptor alpha / Fc fusion protein, can be used to enhance the immune response against neoplasia (e.g., glioblastoma, prostate cancer, blood cancer, B-cell neoplasms, multiple myeloma, B-cell lymphoma, Hodgkin's lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia, cutaneous T-cell lymphoma, T-cell lymphoma, solid tumors, urothelial / bladder cancer, melanoma, lung cancer, renal cell carcinoma, breast cancer, gastric and esophageal cancer, head and neck cancer, colorectal cancer, ovarian cancer, non-small cell lung cancer, B-cell non-Hodgkin's lymphoma, and squamous cell head and neck cancer) or infection (e.g., viral infection with human immunodeficiency virus).
[0005] A method for treating neoplasia or infection in a subject by administering to the subject an effective amount of an antibody (or antibody-like molecule) and an effective amount of a pharmaceutical composition comprising an IL-15N72D:IL-15RαSu / Fc complex (ALT-803), wherein the ALT-803 comprises a dimeric IL-15RαSu / Fc and two IL-15N72D molecules. In one aspect, the IL-15N72D molecule comprises SEQ ID NO: 3. An exemplary IL-15RαSu / Fc comprises SEQ ID NO: 6.
[0006] The subject is preferably a mammal in need of such treatment, such as a subject that has been diagnosed with a neoplasia or infection or a predisposition thereof. The mammal is any mammal, such as a human, a primate, a mouse, a rat, a dog, a cat, a horse, and livestock or domesticated animals for food, such as cattle, sheep, chickens and goats. In a preferred embodiment, the mammal is a human.
[0007] Neoplasias suitable for treatment using the methods disclosed herein include glioblastoma, prostate cancer, acute myeloid leukemia, B-cell neoplasms, multiple myeloma, B-cell lymphoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, cutaneous T-cell lymphoma, T-cell lymphoma, solid tumors, urothelial / bladder cancer, melanoma, lung cancer, renal cell carcinoma, breast cancer, gastric cancer and esophageal cancer, head and neck cancer, colorectal cancer, and ovarian cancer. An exemplary infection treated using the methods disclosed herein is human immunodeficiency virus (HIV) infection. The methods disclosed herein can also be used to treat bacterial infections (e.g., Gram-positive bacteria or Gram-negative bacteria) (Oleksiewicz et al. 2012. Arch Biochem Biophys. 526: 124-31).
[0008] Preferably, administration of the compositions disclosed herein also prevents further recurrence of neoplasia or infection following treatment of the disease.
[0009] In addition, the methods of the present invention can be used for the effective treatment of autoimmune diseases, wherein the inhibition or reduction of cells associated with the autoimmune response provides clinical benefits to patients. Such cells include leukocytes, particularly B cells or T cells, and such autoimmune diseases include rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, Crohn's disease, ulcerative colitis, multiple sclerosis, ankylosing spondylitis, type 1 diabetes, and systemic lupus erythematosus (Chan et al. 2010. Nat Rev Immunol. 10: 301-16).
[0010] 700, 800, or 900 μg / kg body weight, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg / kg body weight.
[0011] In some examples, ALT-803 is administered daily, such as once every 24 hours. Alternatively, ALT-803 is administered continuously every day, or several times a day, such as once every 1 hour, such as once every 2 hours, once every 3 hours, once every 4 hours, once every 5 hours, such as once every 6 hours, once every 7 hours, once every 8 hours, once every 9 hours, once every 10 hours, once every 11 hours, or once every 12 hours.
[0012] Exemplary effective daily dosages of ALT-803 include between 0.1 μg / kg and 100 μg / kg body weight, e.g., 0.1, 0.3, 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 99 μg / kg body weight.
[0013] Alternatively, ALT-803 is administered approximately once per week, such as approximately once every 7 days. Alternatively, ALT-803 is administered twice per week, three times per week, four times per week, five times per week, six times per week, or seven times per week. Exemplary effective weekly doses of ALT-803 include between 0.0001 mg / kg and 4 mg / kg body weight, such as 0.001, 0.003, 0.005, 0.01. 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, or 4 mg / kg body weight. For example, an effective weekly dose of ALT-803 is between 0.1 μg / kg body weight and 400 μg / kg body weight. Alternatively, the dosage may be fixed or based on body surface area (i.e., per m 2 ) and administered ALT-803.
[0014] In some instances, subjects receive two 6-week cycles, each cycle consisting of 4 weeks of intravenous dosing of ALT-803 followed by a 2-week rest period. Essentially, the attending physician or veterinarian determines the appropriate amount and dosing regimen.
[0015] The compositions disclosed herein are administered systemically, intravenously, subcutaneously, intramuscularly, intravesically, or by infusion. The antibody and ALT-803 may be administered simultaneously or sequentially.
[0016] The antibody (Ab) is preferably a tumor-specific antibody, an immune checkpoint inhibitor, or an antiviral antibody. Preferably, the antibody is composed of heavy chain and light chain immunoglobulin (Ig) proteins, which may include rodent type, human type, chimeric type and humanized form. In addition, the method disclosed herein may use antibody-like molecules, such as molecules comprising antigen binding domains (e.g., single-chain antibodies, Fab, Fv, T cell receptor binding domains, ligand binding domains, or receptor binding domains). In some examples, these domains are preferably linked to Fc domains. The Ig can be any known isotype (e.g., IgA, IgD, IgE, IgG, IgG1, IgG2, IgG3, IgG4, IgG2a, IgG2b, and IgM). In some applications disclosed herein using infected targeting Ab (or antibody-like molecules), the Ab (or antibody-like molecules) contains heavy chains or Fc domains that can react with Fc receptors to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and / or antibody-dependent cellular phagocytosis (ADCP). In other examples, antibodies conjugated to effector molecules may be used. In other applications such as the use of immune checkpoint blockers, it is preferred that the Ab (or antibody-like molecule) contains a heavy chain or Fc domain (eg, IgG4 Fc) that cannot effectively mediate ADCC or ADCP.
[0017] In certain embodiments, the antigen used for the antibody comprises a cell surface receptor or ligand. In another embodiment, the antigen comprises a CD antigen, a cytokine or chemokine receptor or ligand, a growth factor receptor or ligand, a tissue factor, a cell adhesion molecule, an MHC / MHC-like molecule, an Fc receptor, a Toll-like receptor, a NK receptor, a TCR, a BCR, a positive / negative costimulatory receptor or ligand, a death receptor or ligand, a tumor-associated antigen, or an antigen encoded by a virus.
[0018] The tumor-specific antibody preferably binds to an antigen on a tumor cell. Tumor-specific antibodies approved for use in treating cancer patients include rituximab, ofatumumab, and obinutuzumab (anti-CD20 Abs); trastuzumab and pertuzumab (anti-HER2 Abs); cetuximab and panitumumab (anti-EGFR Abs); and alemtuzumab (anti-CD52 Ab). Similarly, antibodies with CD20 ( 90 Y-labeled Ibritumomab, 131Antibody-effector molecule conjugates specific for HER2 (trastuzumab emtansine), CD30 (brentuximab vedotin), and CD33 (gemtuzumab tuzumab) have been approved for cancer treatment (Sliwkowski MX, Mellman I. 2013 Science 341: 1192).
[0019] In addition, the preferred antibodies of the present invention may include a variety of other tumor-specific antibodies known in the art. These antibodies for treating cancer and their respective targets include, but are not limited to, nivolumab (anti-PD-1Ab), TA99 (anti-gp75), 3F8 (anti-GD2), 8H9 (anti-B7-H3), abagovomab (anti-CA-125 (copycat)), adecatumumab (anti-EpCAM), afutuzumab (anti-CD20), alacizumab pegol (anti-VEGFR2), altumomab pentetate (anti-CEA), amatuximab (anti-mesothelin), AME-133 (anti-CD20), anatumomab mafenatox (anti-TAG-72), apolizumab (anti-HLA-DR), acitumomab (anti-CEA), baviximab (anti-phosphatidylserine), betumomab (anti-CD22), belimumab (anti-BAFF), besilesomab (anti-CEA-related antigen), bevacizumab (anti-VEGF-A), bivatuzumab mertansine (anti-CD44 v6), blinatumomab (anti-CD19), BMS-663513 (anti-CD137), brentuximab vedotin (anti-CD30 (TNFRSF8)), cantuzumab mertansine (anti-mucin CanAg), cantuzumab ravtansine (anti-MUC1), capromab pendetide (anti-prostate cancer cells), carlumab (anti-MCP-1), catumaxomab (anti-EpCAM, CD3), cBR96-doxorubicin immunoconjugate (anti-Lewis-Y antigen), CC49 (anti-TAG-72), cedelizumab (anti-CD4), Ch.14.18 (anti-GD2), ch-TNT (anti-DNA-associated antigen), citatuzumab bogatox (anti-EpCAM), cixutumumab (anti-IGF-1 receptor), clivatuzumabtetraxetan (anti-MUC1), conatumumab (anti-TRAIL-R2), CP-870893 (anti-CD40), dacetuzumab (anti-CD40), daclizumab (anti-CD25), dalotuzumab (anti-insulin-like growth factor I receptor), daratumumab (anti-CD38 (cyclic ADP ribose hydrolase)), demcizumab (anti-DLL4), detumomab (anti-B lymphoma cells), drozit umab (anti-DR5), duligotumab (anti-HER3), dusigitumab (anti-ILGF2), ecoromeximab (anti-GD3 ganglioside), edrecolomab (anti-EpCAM), elotuzumab (anti-SLAMF7), elsilimomab (anti-IL-6), enavatuzumab (anti-TWEAK receptor), enoticumab (anti-DLL4), ensituximab (anti-5AC), epitumomab cituxetan (anti-episialin), epratuzumab (anti-CD22), ertumaxomab (anti-HER2 / neu, CD3), etaracizumab (anti-integrin ανβ3), faralimomab (anti-interferon receptor), farletuzumab (anti-folate receptor 1), FBTA05 (anti-CD20), ficlatuzumab (anti-HGF), figitumumab (anti-IGF-1 receptor), flanvotumab (anti-TYRP1 (glycoprotein 75)), fresolimumab (anti-TGFβ), futuximab (anti-EGFR), galiximab (anti-CD80), ganitumab (anti-IGF-I), gemtuzumab ozogamicin (anti-CD33), girentuximab (anti-carbonic anhydrase 9 (CA-IX)), glembatumumab vedotin (anti-GPNMB), guselkumab (anti-IL13), ibalizumab (anti-CD4), ibritumomabtiuxetan (anti-CD20), icrucumab (anti-VEGFR-1), igovomab (anti-CA-125), IMAB362 (anti-CLDN18.2), IMC-CS4 (anti-CSF1R), IMC-TR1 (TGFβRII), imgatuzumab (anti-EGFR), inclacumab (anti-selectin P), indatuximabravtansine (anti-SDC1), inotuzumab ozogamicin (anti-CD22), intetumumab (anti-CD51), ipilimumab (anti-CD152), iratumumab (anti-CD30 (TNFRSF8)), KM3065 (anti-CD20), KW-0761 (anti-CD194), LY2875358 (anti-MET) labetuzumab (anti-CEA), lambrolizumab (anti-PDCD1), lexatumumab (anti-TRAIL-R2), lintuzumab (anti-CD33), lirilumab (anti-KIR2D), lorvotuzumab mertansine (anti-CD56), lucatumumab (anti-CD40), lumiliximab (anti-CD23 (IgE receptor)), mapatumumab (anti-TRAIL-R1), margetuximab (anti-CH4D5), matuzumab (anti-EGFR), mavrilimumab (anti-GMCSF receptor a chain), milatuzumab (anti-CD74), minretumomab (anti-TAG-72), mitumomab (anti-GD3 ganglioside), mogamulizumab (anti-CCR4), moxetumomab pasudotox (anti-CD22), nacolomab tafenatox (anti-C242 antigen), naptumomab estafenatox (anti-5T4), narnatumab (anti-RON), necitumumab (anti-EGFR), nesvacumab (anti-angiopoietin 2), nimotuzumab (anti-EGFR), nivolumab (anti-IgG4), nofetumomab merpentan, ocrelizumab (anti-CD20), ocaratuzumab (anti-CD20), olaratumab (anti-PDGF-Rα), onartuzumab (anti-c-MET), ontuxizumab (anti-TEM1), oportuzumabmonatox (anti-EpCAM), oregovomab (anti-CA-125), otlertuzumab (anti-CD37), pankomab (anti-tumor-specific glycosylation of MUC1), parsatuzumab (anti-EGFL7), pascolizumab (anti-IL-4), patritumab (anti-HER3), pemtumomab (anti-MUC1), pertuzumab (anti-HER2 / neu), pidilizumab (anti-PD-1), pinatuzumab vedotin (anti-CD22), pintumomab (anti-adenocarcinoma antigen), polatuzumab vedotin (anti-CD79B), pritumumab (anti-vimentin), PR0131921 (anti-CD20), quilizumab (anti-IGHE), racotumomab (anti-N-glycolylneuraminic acid), radretumab (anti-fibronectin extradomain B), ramucirumab (anti-VEGFR2), rilotumumab (anti-HGF), robatumumab (anti-IGF-1 receptor), roledumab (anti-RHD), rovelizumab (anti-CD11 and CD18), samalizumab (anti-CD200), satumomab pendetide (anti-TAG-72), seribantumab (anti-ERBB3), SGN-CD19A (anti-CD19), SGN-CD33A (anti-CD33), sibrotuzumab (anti-FAP), siltuximab (anti-IL-6), solitomab (anti-EpCAM), sontuzumab (anti-episialin), tabalumab (anti-BAFF), tacatuzumab tetraxetan (anti-α-fetoprotein), taplitumomab paptox (anti-CD19), telimomabaritox, tenatumomab (anti-consolidated protein C), teneliximab (anti-CD40), teprotumumab (anti-CD221), TGN1412 (anti-CD28), ticilimumab (anti-CTLA-4), tigatuzumab (anti-TRAIL-R2), TNX-650 (anti-IL-13), tositumomab (anti-CS20), tovetumab (anti-CD140a), TRBS07 (anti-GD2), tregalizumab (anti-CD4), tremelimumab (anti-CTLA-4), TRU-016 (anti-CD37), tucotuzumab celmoleukin (anti-EpCAM), ublituximab (anti-CD20), urelumab (anti-4-1BB), vantictumab (anti-frizzled receptor), vapaliximab (anti-AOC3 (VAP-1)), vatelizumab (anti-ITGA2), veltuzumab (anti-CD20), vesencumab (anti-NRP1), visilizumab (anti-CD3), volociximab (anti-integrin α5β1), vorsetuzumab mafodotin (anti-CD70), votumumab (anti-tumor antigen CTAA16.88), zalutumumab (anti-EGFR), zanolimumab (anti-CD4), zatuximab (anti-HER1), ziralimumab (anti-CD147 (basigin)), RG7636 (anti-ETBR), RG7458 (anti-MUC16), RG7599 (anti-NaPi2b), MPDL3280A (anti-PD-L1), RG7450 (anti-STEAP1), and GDC-0199 (anti-Bc1-2).
[0020] Other antibodies or tumor target binding proteins (e.g., TCR domains) that can be used in the present invention include, but are not limited to, those that bind to the following antigens (cancer markers represent non-limiting examples): aminopeptidase N (CD13), annexin A1, B7-H3 (CD276, various cancers), CA125 (ovarian cancer), CA15-3 (cancer), CA19-9 (cancer), L6 (cancer), Lewis Y (cancer), Lewis X (cancer), alpha-fetoprotein (cancer), CA242 (colorectal cancer), placental alkaline phosphatase (cancer), prostate-specific antigen (prostate cancer), prostatic acid phosphatase (prostate cancer), epidermal growth factor (cancer), CD2 (Hodgkin's disease, NHL lymphoma, multiple myeloma), CD3ε (T-cell lymphoma, lung cancer, breast cancer, gastric cancer, ovarian cancer, autoimmune disease, malignant ascites), CD19 (B-cell malignancies), CD20 (non-Hodgkin's lymphoma, B-cell tumors, autoimmune diseases), CD21 (B-cell lymphoma), CD22 (leukemia, lymphoma, multiple myeloma, SLE), CD30 (Hodgkin's lymphoma), CD33 (leukemia, autoimmune diseases), CD38 (multiple myeloma), CD40 (lymphoma, multiple myeloma, leukemia (CLL)), CD 51 (metastatic melanoma, sarcoma), CD52 (leukemia), CD56 (small cell lung cancer, ovarian cancer, Merkel cell carcinoma, and lipid tumors, multiple myeloma), CD66e (cancer), CD70 (metastatic renal cell carcinoma and non-Hodgkin's lymphoma), CD74 (multiple myeloma), CD80 (lymphoma), CD98 (cancer), CD123 (leukemia), mucin (cancer), CD221 (solid tumors), CD227 (breast cancer, ovarian cancer), CD262 (NSCLC and other cancers), CD309 (ovarian cancer), CD326 (solid tumors), CEACAM3 (colorectal cancer, gastric cancer), CEACAM5 (CEA, CD66e) (breast cancer, colorectal cancer and lung cancer), DLL4 (A-like-4), EGFR (multiple cancers), CTLA4 (melanoma), CXCR4 (CD 184, heme-oncology, solid tumors), Endoglin (CD105, solid tumors), EPCAM (epithelial cell adhesion molecule, bladder cancer, head and neck cancer, colon cancer, NHL prostate cancer, and ovarian cancer), ERBB2 (lung cancer, breast cancer, prostate cancer), FCGR1 (autoimmune diseases), FOLR (folate receptor, ovarian cancer), FGFR (cancer), GD2 ganglioside (cancer), G-28 (cell surface antigen glycolipid, melanoma), GD3 ideotype (cancer), heat shock protein (cancer), HER1 (lung cancer, gastric cancer), HER2 (breast cancer, lung cancer, and ovarian cancer), H LA-DR10 (NHL), HLA-DRB (NHL, B-cell leukemia), human chorionic gonadotropin (cancer), IGF1R (solid tumors, blood cancers), IL-2 receptor (T-cell leukemia and lymphoma), IL-6R (multiple myeloma, RA, Castleman's disease, IL6-dependent tumors), integrins (ανβ3, α5β1, α6β4, α11β3, α5β5, ανβ5, for multiple cancers), MAGE-1 (cancer), MAGE-2 (cancer), MAGE-3 (cancer), MAGE 4 (cancer), anti-transferrin receptor (cancer), p97 (melanoma), MS4A1 (transmembrane 4 domains subfamily A member 1, non-Hodgkin's B-cell lymphoma, leukemia), MUC1 (breast cancer, ovarian cancer, cervical cancer, bronchial cancer and gastrointestinal cancer), MUC16 (CA125) (ovarian cancer), CEA (colorectal cancer), gp1OO (melanoma), MARTI (melanoma), MPG (melanoma), MS4A1 (transmembrane 4 domains subfamily A, small cell lung cancer, NHL), nucleolin, Neu oncogene product (cancer), P21 (cancer), connexin-4 (cancer), antibody complement (N-glycolylneuraminic acid, breast cancer, melanoma cancer), PLAP-like testicular alkaline phosphatase (ovarian cancer, testicular cancer), PSMA (anterior lacrimal gland tumors), PSA (prostate cancer), ROB04, TAG 72 (tumors associated with glycoprotein 72, AML, gastric cancer, colorectal cancer, ovarian cancer), T-cell transmembrane protein (cancer), Tie (CD202b), tissue factor, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, cancer), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B, multiple myeloma, NHL, other cancers, RA and SLE), TPBG (trophoblast glycoprotein, renal cell carcinoma), TRAIL-R1 (tumor necrosis apoptosis-inducing ligand receptor 1, lymphoma, NHL, colorectal cancer, lung cancer), VCAM-1 (CD 106, melanoma), VEGF, VEGF-A, VEGF-2 (CD309) (multiple cancers). Some other tumor-associated antigen targets have been reviewed (Gerber, et al, mAbs 2009 1:247-253; Novellino et al, mAbs 2009 1:247-253; Novellino et al, mAbs 2009 1:247-253).al, Cancer Immunol Immunother. 2005 54: 187-207; Franke, et al, Cancer Biother Radiopharm. 2000, 15: 459-76; Guo, et al., Adv Cancer Res. 2013; 119: 421-475, Parmiani et al. J Immunol. 2007, 178: 1975-9). These antigens include clusters of differentiation (CD4, CD5, CD6, CD7, CD8, CD9, CD 10. CD11a, CD11b, CD11c, CD12w, CD14, CD15, CD16, CDw17, CD18, CD21, CD23, CD24, CD25, CD26 , CD27, CD28, CD29, CD31, CD32, CD34, CD35, CD36, CD37, CD41, CD42, CD43, CD44, CD45, CD46, CD 47. CD48, CD49b, CD49c, CD53, CD54, CD55, CD58, CD59, CD61, CD62E, CD62L, CD62P, CD63, CD68 , CD69, CD71, CD72, CD79, CD81, CD82, CD83, CD86, CD87, CD88, CD89, CD90, CD91, CD95, CD96, CD 100. CD103, CD105, CD106, CD109, CD117, CD120, CD127, CD133, CD134, CD135, CD138, CD141, C D142, CD143, CD144, CD147, CD151, CD152, CD154, CD156, CD158, CD163, CD166,.CD168, CD184, CDw186, CD195, CD202 (a, b), CD209, CD235a, CD271, CD303, CD304), annexin A1, nucleolin, endoglin (CD105), ROB04, aminopeptidase N-like-4 (DLL4), VEGFR-2 (CD309), CXCR4 (CD184), Tie2, B7-H3, WT1, MUC1, LMP2, HPV E6E7, EGFRvIII, HER-2 / neu, idiotype, MAGEA3, p53 non-mutant, NY-ESO-1, GD2, CEA, MelanA / MART1, Ras mutant, gp1OO, p53 mutant, proteinase 3 (PR1), bcr-ab1, tyrosinase, survivin, hTERT, sarcoma migration interruption point, EphA2, PAP, ML-IAP, AFP, EpCAM, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, ALK, androgen receptor, cyclin B 1, polysialic acid, MYCN, RhoC, TRP-2, GD3, fucosyl GM1, mesothelin, PSCA, MAGE A1, sLe(a), CYPIB I, PLAC1, GM3, BORIS, Tn, GloboH, ETV6-AML, NY-BR-1, RGS5, SART3, STn, carbonic anhydrase IX, PAX5, OY-TES1, protamine 17, LCK, HMWMAA, AKAP-4, SSX2, XAGE 1, B7H3, betaine, Tie 2, Page4, VEGFR2, MAD-CT-1, FAP, PDGFR-β, MAD-CT-2, and Fos-related antigen 1.
[0021] Furthermore, preferred antibodies of the present invention include those known in the art to have specificity for antigenic and epitopic targets associated with infected cells. Such targets include, but are not limited to, targets from the following pathogenic agents of interest: HIV virus (particularly antigens derived from HIV envelope spike and / or gp120 and gp41 epitopes), human papillomavirus (HPV), Mycobacterium tuberculosis, Streptococcus agalactiae, methicillin-resistant Staphylococcus aureus, Legionella pneumophila, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Cryptococcus neoformans, Histoplasma capsulatum, Haemophilus B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Bacillus abortus, rabies virus, influenza virus, cytomegalovirus, herpes simplex virus I, herpes simplex virus II, human serum parvovirus-like virus, respiratory syncytial virus, varicella-zoster virus, hepatitis B virus, hepatitis C virus, measles virus, adenovirus, human T-cell leukemia virus, Epstein-Barr virus, n-Barr virus, murine leukemia virus, mumps virus, vesicular stomatitis virus, Sindbis virus, lymphocytic choriomeningitis virus, wart virus, bluetongue virus, Sendai virus, feline leukemia virus, reovirus, polio virus, simian virus 40, mouse mammary tumor virus, dengue virus, rubella virus, West Nile virus, Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trypanosoma lamblia Trypanosoma cruzi, Trypanosoma rhodesiense, Trypanosoma brucei, Schistosoma mansoni, Schistosoma japonicum, Babesia bovis, Eimeria tenella, Onchocerca volvulus, Leishmania, Trichinella spiralis, Theileria parvula, Taenia fowleri, Tapeworm, Taenia solium, Echinococcus granulosus, Mesogenum cohenii, Mycoplasma arthritis, Mycoplasma hyorhinis, Mycoplasma oralis, Mycoplasma arginini, Acholeplasma rabbis, Mycoplasma salivarius and Mycoplasma pneumoniae.
[0022] In other specific embodiments, the antibody (or antibody-like molecule) has specificity for an immune checkpoint molecule or its ligand, and is used as an inhibitor of immune checkpoint suppression activity or as an agonist of immune checkpoint stimulation activity. Such immune checkpoint molecules and ligands include PD1, PDL1, PDL2, CTLA4, CD28, CD80, CD86, B7-H3, B7-H4, B7-H5, ICOS-L, ICOS, BTLA, CD137L, CD137, HVEM, KIR, 4-1BB, OX40L, CD70, CD27, OX40, GITR, IDO, TIM3, GAL9, VISTA, CD155, TIGIT, LIGHT, LAIR-1, Siglecs and A2aR (Pardoll DM. 2012. Nature Rev Cancer 12: 252-264; Thaventhiran T, et al. 2012. J Clin Cell Immunol S12: 004). In addition, preferred antibodies of the present invention include ipilimumab and tremelimumab (anti-CTLA4), nivolumab, pembrolizumab, pidilizumab, TSR-042, ANB011, AMP-514 and AMP-224 (ligand-Fc fusion) (anti-PD1), MPDL3280A, MEDI4736, MEDI0680, and BMS-9365569 (anti-PDL1), MEDI6469 (anti-OX40 agonist), BMS-986016, IMP701, IMP731, and IMP321 (anti-LAG3).
[0023] In one aspect, adding ALT-803 to antibody therapy in vitro or in vivo increases the cytotoxicity of immune cells against infected or disease-associated cells. In some instances, ALT-803 can stimulate immune cells to amplify ADCC or ADCP activity mediated by disease-specific antibodies (or antibody-like molecules) against tumors, infected or autoimmune disease-associated cells. In a specific embodiment, the use of ALT-803 to treat immune cells increases ADCC or ADCP activity against disease-associated infected cells by disease-targeted specific antibodies by at least 5%, such as at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%. In a preferred embodiment, immune cells are treated with ALT-803 and used to kill tumor cells via ADCC or ADCP mediated by a tumor-specific antibody, wherein the level of tumor cell death is at least 5% or more, such as at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% greater than the level obtained using immune cells not treated with ALT-803. In a preferred embodiment, after administration of ALT-803 and the antibody, tumor-specific ADCC or ADCP in the subject is increased by at least 5%, such as at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%. In a particular embodiment, NK cell-based ADCC activity is increased by ALT-803 treatment.
[0024] In other examples, ALT-803 stimulates CD4 + and CD8 +T cells to kill diseased or disease-associated cells, such as tumor cells or infected cells. Preferably, ALT-803 treatment stimulates the cytolytic activity of immune cells, while immune checkpoint blocker treatment inhibits the immune suppression response, so that the combination of these treatments provides more effective and / or longer-lasting activity against tumors or infected cells. In some specific embodiments, ALT-803 increases serum levels of interferon gamma (IFN-γ) and / or IL-6, stimulates the proliferation of NK cells and T cells, and upregulates NK cell and T cell expression of activation markers including CD25, CD69, perforin and granzymes. The introduction of these markers can enhance the responsiveness or cytolytic activity of immune cells against infected cells. For example, the methods disclosed herein stimulate NK cells to kill tumors or infected cells.
[0025] In other specific embodiments, ALT-803 induces the activity and / or level of other innate immune cells including neutrophils or monocytes. Such cells are known to mediate ADCC and ADCP of therapeutic antibodies against diseased cells such as tumor cells or infected cells (Golay, et al. Blood. 2013 122: 3482-91; Richards, et al, Mol Cancer Ther 2008 7: 2517-27). Preferably, the combination therapy of ALT-803 and antibodies provides an improved clinical response for patients with cancer or infection, and the therapeutic mechanism is at least partially mediated by innate immune cells. For example, the methods disclosed herein stimulate neutrophils or monocytes to kill tumor or infected cells.
[0026] Preferably, the methods disclosed herein result in a decrease / reduction in the number of tumors or infected cells compared to the number of tumors or infected cells prior to administration of the compositions of the invention. Alternatively, the methods disclosed herein result in a decrease in disease progression of the neoplasia or infection. Preferably, the methods disclosed herein result in a longer survival time of a subject compared to the survival time of an untreated subject.
[0027] In some examples, the method for treating neoplasia or infection in a subject is performed by administering to the subject an effective amount of Bacillus Calmette-Guérin (BCG) and an effective amount of a pharmaceutical composition comprising ALT-803, wherein the ALT-803 comprises a dimeric IL-15RαSu / Fc and two IL-15N72D molecules. For example, the subject receives BCG plus ALT-803 weekly via a catheter placed in the bladder for 6 weeks.
[0028] Also provided is a kit for treating a neoplasia, the kit comprising an effective amount of ALT-803, an antibody, and instructions for using the kit to treat a neoplasia.
[0029] The kit for treating an infection comprises an effective amount of ALT-803, an antibody, and instructions for using the kit to treat an infection.
[0030] In certain aspects of the soluble fusion protein complex of the present invention, the IL-15 polypeptide is an IL-15 mutant having an amino acid sequence different from that of a native IL-15 polypeptide. Herein, human IL-15 polypeptides are referred to as huIL-15, hIL-15, huIL15, hIL15, IL-15 wild type (wt), and mutants thereof are referred to as using natural amino acids and mutant amino acids at their positions in the mature sequence. For example, huIL15N72D refers to human IL-15, which comprises a substitution of N at position 72 with D. On the one hand, the IL-15 mutant functions as an IL-15 agonist, as indicated by an increase in binding activity to the IL-15RβγC receptor compared to the native IL-15 polypeptide.
[0031] Alternatively, the IL-15 mutant functions as an IL-15 antagonist, as indicated by reduced binding activity to the IL-15RβγC receptor compared to the native IL-15 polypeptide.
[0032] The method for killing a target cell is carried out by contacting a plurality of cells with an antibody and ALT-803, wherein the plurality of cells further include an immune cell bearing an IL-15R chain recognized by an IL-15 domain, or an immune cell bearing an Fc receptor chain recognized by an Fc domain, and a target cell bearing an antigen recognized by the antibody (e.g., an anti-CD20 antibody), and killing the target cell. For example, the target cell is a tumor cell or an infected cell (e.g., a virus-infected cell).
[0033] The method for killing diseased cells expressing a target antigen is implemented by treating immune cells with an effective amount of IL-15N72D:IL-15RαSu / Fc complex (ALT-803), mixing the ALT-803-treated immune cells with antibodies specific to the target antigen and diseased cells expressing the target antigen, and killing the diseased cells via ADCC or ADCP mediated by the ALT-803-treated immune cells and the target antigen-specific antibody. In one aspect, the method provides at least 5% increase in killing of diseased cells compared to that mediated by cells not treated with ALT-803, such as at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%.
[0034] The present invention also provides a method for preventing or treating a disease in a patient, wherein the diseased cells express an antigen associated with the disease, the method comprising the steps of contacting a plurality of cells with an antibody and ALT-803, and destroying or killing the diseased cells sufficient to prevent or treat the disease in the patient. In preferred embodiments, combination therapy using ALT-803 and the antibody can reduce disease progression and / or prolong patient survival.
[0035] The present invention provides a method of stimulating an immune response in a mammal by administering to the mammal an effective amount of an antibody and an effective amount of ALT-803.
[0036] Except for those excluded by definition, all scientific and technological terms used herein have the meanings generally understood by those skilled in the art. The following references provide the general definitions of most of the terms used in the present invention to the technician: "Microbiology and Molecular Biology Dictionary (Second Edition)" (Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed.1994)); "Cambridge Dictionary of Science and Technology" (The Cambridge Dictionary of Science and Technology (Walker ed., 1988)); "Glossary of Genetics" (The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991)); and, "Harper Collins Biology Dictionary" (Hale & Marham, The Harper Collins Dictionary of Biology (1991)). Herein, unless explicitly excluded, the following terms have the meanings disclosed below.
[0037] "Agent" means a peptide, a nucleic acid molecule, or a small compound. An exemplary therapeutic agent is ALT-803.
[0038] "ALT-803" refers to a complex comprising IL-15N72D non-covalently associated with a dimeric IL-15RαSu / Fc fusion protein and having immunostimulatory activity. In a specific embodiment, the IL-15N72D and / or IL-15RαSu / Fc fusion protein comprises one, two, three, four or more amino acid mutations relative to a reference sequence. An exemplary IL-15N72D amino acid sequence is provided below.
[0039] "Relieve" means to reduce, suppress, weaken, diminish, arrest or stabilize the development or progression of a disease.
[0040] "Analog" means a molecule that is different but has similar functional or structural features. For example, a polypeptide analog retains the biological activity relative to the native polypeptide while having certain biochemical modifications that enhance the function of the analog relative to the native polypeptide. Such biochemical modifications may increase the analog's resistance to proteases, membrane permeability, or half-life without altering, for example, ligand binding. Analogs may include non-natural amino acids.
[0041] The present invention includes antibodies or fragments of such antibodies, as long as they exhibit the desired biological activity. The present invention also includes chimeric antibodies, such as humanized antibodies. Generally, humanized antibodies have one or more amino acid residues introduced from their non-human sources. For example, humanization can be implemented by replacing at least part of the complementarity determining region of rodents with the corresponding region of human antibodies using the method disclosed in the field.
[0042] The term "antibody" or "immunoglobulin" tends to encompass both polyclonal and monoclonal classes. Preferred antibodies are monoclonal antibodies that react with antigens. The term "antibody" also tends to encompass mixtures of more than one antibody that reacts with an antigen (e.g., a cocktail mixture of different types of monoclonal antibodies that react with an antigen). The term "antibody" further tends to encompass complete antibodies, their biologically functional fragments, single-chain antibodies, and genetically altered antibodies such as chimeric antibodies, bifunctional antibodies, antibody conjugates, humanized and human antibodies that contain sites from more than one species. Biologically functional antibodies that may also be used are peptide fragments of antibodies that are derived from antibodies that are sufficiently bound to an antigen. Herein, "antibody" is meant to include whole antibodies and any antibody fragments (e.g., F(ab')2, Fab', Fab, Fv) that can bind to an epitope, an antigen, or an antigen fragment of interest.
[0043] "Binding to" a molecule means having a physicochemical affinity for that molecule.
[0044] "Detection" refers to identifying the presence, absence, or amount of an analyte to be detected.
[0045] "Disease" means any condition or disorder that destroys or interferes with the normal function of a cell, tissue, or organ. Examples of diseases include neoplasia and infection.
[0046] The terms "effective amount" and "therapeutically effective amount" of a formulation or formulation component mean that the amount of the formulation or component, used alone or in combination, is sufficient to provide the desired effect. For example, "effective amount" means the amount of a compound, used alone or in combination, required to relieve the symptoms of a disease relative to an untreated patient. The effective amount of an active compound for therapeutic treatment of a disease used to practice the present invention varies depending on the mode of administration and the age, weight and general health of the subject. Basically, the attending physician or veterinarian will determine the appropriate amount and dosage regimen. This amount is referred to as an "effective" amount.
[0047] A "fragment" is a portion of an inhibitory polypeptide or nucleic acid molecule. This portion preferably contains at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the overall length of the reference nucleic acid molecule or polypeptide. For example, a fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids. However, the present invention also encompasses polypeptides and nucleic acid fragments as long as they exhibit the desired biological activity exhibited by the full-length polypeptide and nucleic acid, respectively. Nucleotide fragments of almost any length may be used. For example, exemplary polynucleotide fragments having a total length of about 10,000, about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base pairs (including all intermediate lengths) are included in most implementations of the invention. Similarly, polypeptide fragments of almost any length can be used. For example, exemplary polynucleotide fragments having a total length of about 10,000, about 5,000, about 3,000, about 2,000, about 1,000, about 5,000, about 1,000, about 500, about 200, about 100, or about 50 amino acids (including all intermediate lengths) are included in most implementations of the invention.
[0048] The terms "isolated," "purified," or "biologically pure" refer to a material that is free, to varying degrees, from normally associated components found in its native state. "Isolated" means the degree of separation from the original source or surrounding material. "Purity" means a degree of separation greater than isolated.
[0049] A "purified" or "biologically pure" protein is sufficiently free of other materials so that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, the nucleic acids or peptides of the present invention are substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA technology, and are also free of chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, such as polyacrylamide gel electrophoresis or high performance liquid chromatography. The term "purified" can mean that the nucleic acid or protein produces substantially one band in an electrophoretic gel. For proteins that can be modified, such as phosphorylation or glycosylation, different modifications may produce different isolated proteins, which can be purified separately.
[0050] Likewise, "substantially pure" means a nucleotide or polypeptide that has been separated from its naturally associated components. Typically, nucleotides and polypeptides are substantially pure when they are at least 60%, 70%, 80%, 90%, 95%, or even 99% free, by weight, of the proteins and natural organic molecules with which they are naturally associated.
[0051] "Isolated nucleic acid" means a nucleic acid that does not contain the genes that flank it in the native genome of the organism from which the nucleic acid is derived. The term covers, for example: (a) a DNA that is part of a natural genomic DNA molecule, but is not flanked on both sides by nucleic acid sequences that flank the molecule in the native genome of the organism; (b) a nucleic acid that is incorporated into a vector or into the genomic DNA of a prokaryotic or eukaryotic cell in a manner such that the resulting molecule is not identical to any native vector or genomic DNA; (c) an independent molecule such as a cDNA, a genomic fragment, a fragment produced by the polymerase chain reaction (PCR), or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein. The isolated nucleic acid molecules according to the present invention further include synthetically produced molecules, as well as any nucleic acid that has been chemically modified and / or has a modified backbone. For example, an isolated nucleic acid is a purified cDNA or RNA polynucleotide. An isolated nucleic acid molecule also includes a messenger ribonucleic acid (mRNA) molecule.
[0052] By "isolated polypeptide" is meant a polypeptide of the invention that has been separated from its naturally associated components. Typically, a polypeptide is isolated when at least 60% of its weight is free of its naturally associated proteins and naturally occurring organic molecules. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99% polypeptide of the invention by weight. For example, an isolated polypeptide of the invention can be obtained by extraction from a natural source, by expression of a recombinant nucleic acid encoding the polypeptide, or by chemically synthesizing the protein. Purity can be measured by any suitable method, such as column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
[0053] "Marker" means any protein or polynucleotide having a change in expression level or activity that is associated with a disease or disorder.
[0054] "Neoplasia" means a disease or disorder characterized by excessive proliferation or decreased apoptosis. Exemplary neoplasias to which the present invention can be applied include, but are not limited to, leukemias (e.g., acute leukemias, acute lymphocytic leukemias, acute myeloid leukemias, acute myeloblastic leukemias, acute promyelocytic leukemias, acute myelomonocytic leukemias, acute monocytic leukemias, acute erythroleukemias, chronic leukemias, chronic myeloid leukemias, chronic lymphocytic leukemias), polycythemia vera, lymphomas (Hodgkin's, non-Hodgkin's), essential macroglobulinemia, heavy chain diseases, and solid tumors such as sarcomas and carcinomas (e.g., fibrosarcomas, myxosarcoma, liposarcoma ... Liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, stomach cancer and esophageal cancer, head and neck cancer, rectal cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocarcinoma, bile duct cancer, choriocarcinoma, seminoma, embryonal carcinoma, embryonal carcinoma (Wilm's In some embodiments, the invention relates to a method for obtaining a drug, wherein the drug is a tumor, cervical cancer, uterine cancer, testicular cancer, lung cancer, small cell lung cancer, bladder cancer, epithelial cancer, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and retinoblastoma). In particular embodiments, the neoplasia is multiple myeloma, beta cell lymphoma, urothelial / bladder cancer, or pigmented tumor. Herein, "obtaining" in "obtaining a dose" includes synthesizing, purchasing, or other methods of obtaining the dose.
[0055] "Decrease" means a negative change of 5%, 10%, 25%, 50%, 75%, or 100%.
[0056] "Reference" means a standard or control condition.
[0057] A "reference sequence" is a sequence that is defined as a benchmark for sequence comparison. A reference sequence can be a subset or the entirety of a specific sequence; for example, a fragment of a full-length cDNA or gene sequence, or a complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence will generally be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, and even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, and even more preferably about 100 nucleotides or about 300 nucleotides, or about equal to them or any integer therebetween.
[0058] "Specific binding" means that the compound or antibody recognizes and binds to the polypeptide of the present invention, but does not substantially recognize and bind to other molecules in a sample, such as a biological sample, that naturally includes the polypeptide of the present invention.
[0059] Nucleic acid molecules useful in the methods of the present invention include any nucleic acid molecules encoding polypeptides of the present invention or fragments thereof. Such nucleic acid molecules need not be 100% identical to endogenous nucleic acid sequences, but will typically exhibit substantial identity. Polynucleotides having "substantial identity" to endogenous sequences are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the present invention include any nucleic acid molecules encoding polypeptides of the present invention or fragments thereof. Such nucleic acid molecules need not be 100% identical to endogenous nucleic acid sequences, but will typically exhibit substantial identity. Polynucleotides having "substantial identity" to endogenous sequences are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. "Hybridization" means pairing between complementary nucleotide sequences (e.g., genes disclosed herein), or portions thereof, under various stringent conditions to form double-stranded molecules (see, e.g., Wahl, GM and SL Berger (1987) Methods Enzymol. 152: 399; Kimmel, AR (1987) Methods Enzymol. 152: 507).
[0060] For example, stringent salt concentrations will generally be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvents such as formaldehyde, while high stringency hybridization can be obtained in the presence of at least about 35% formaldehyde and more preferably at least about 50% formaldehyde. Stringent temperature conditions will generally include a temperature of at least about 30°C, more preferably at least about 37°C, and most preferably at least about 42°C. It is well known to those skilled in the art to vary additional parameters, such as hybridization time, concentration of detergents such as sodium dodecyl sulfate (SDS), and inclusion and exclusion of carrier DNA. Various levels of stringency are achieved by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formaldehyde, and 100 μg / ml denatured salmon sperm DNA (ssDNA) at 37° C. In a most preferred embodiment, hybridization will occur in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formaldehyde, and 200 μg / ml ssDNA at 42° C. Useful variations on these conditions will be apparent to those skilled in the art.
[0061] For most applications, the washing step after hybridization can also vary in stringency. Washing stringency conditions can be defined by salt concentration and temperature. As described above, washing stringency can be increased by reducing the salt concentration or increasing the temperature. For example, the stringent salt concentration of the washing step is preferably less than about 30mM NaCl and 3mM trisodium citrate, and most preferably less than about 15mM NaCl and 1.5mM trisodium citrate. The stringent temperature conditions of the washing step will generally include a temperature of at least about 25°C, more preferably at least about 42°C, and even more preferably at least about 68°C. In a preferred embodiment, the washing step will occur at 25°C in 30mM NaCl, 3mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, the washing step will occur at 42°C in 15mM NaCl, 1.5mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, the washing step will occur at 68°C in 15mM NaCl, 1.5mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are disclosed in, for example, Benton and Davis (Science 196: 180, 1977), Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72: 3961, 1975), Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001), Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York), and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.
[0062] "Substantially identical" means that a polypeptide or nucleic acid molecule exhibits at least 50% identity to a reference amino acid sequence (e.g., any amino acid sequence disclosed herein) or nucleic acid sequence (e.g., any nucleic acid sequence disclosed herein). Preferably, this sequence has at least 60% identity at the amino acid level or nucleic acid with the sequence used for comparison, more preferably 80% or 85%, and more preferably 90%, 95% or even 99% identity.
[0063] Sequence identity is typically measured using sequence analysis software (e.g., BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs of the sequence analysis software package of the Genetics Computer Group (Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705)). The software matches identical or similar sequences by assigning degrees of homology to various substitutions, eliminations, and / or other modifications. Conservative substitutions typically include substitutions in the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to detecting the degree of identity, the BLAST program can be used, e -3 With e -100 Likelihood levels in between indicate closely related sequences.
[0064] "Subject" means a mammal, including, but not limited to, a human or non-human mammal such as a bovine, equine, canine, ovine or feline. The subject is preferably a mammal in need of such treatment, such as a subject diagnosed with B-cell lymphoma or a predisposition thereof. The mammal is any mammal, such as a human, a primate, a mouse, a rat, a dog, a cat, a horse, and livestock or domesticated animals for food such as cattle, sheep, pigs, chickens and goats. In a preferred embodiment, the mammal is a human.
[0065] The ranges provided herein are understood to be a simplification of all numerical values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or subrange from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
[0066] As used herein, the terms "treating" and "treatment" refer to the administration of an agent or formulation to a clinically symptomatic individual suffering from a deleterious condition, lesion or disease to cause a decrease in severity and / or frequency of symptoms, to eliminate symptoms and / or their underlying causes, and / or to promote improvement or remediation of damage. It should be understood that, although not excluded, treatment of a lesion or condition does not require complete elimination of the lesion, condition or symptoms associated therewith.
[0067] Treatment of patients with neoplasia may include any of the following: adjuvant therapy (also called adjuvant therapy or adjunctive therapy), which destroys residual tumor cells that are thought to be present after initial therapy (e.g., surgery) removes a known tumor, thereby preventing possible recurrence of the cancer; neoadjuvant therapy, which is given before surgery to shrink the cancer; induction therapy, which causes a remission, typically for acute leukemias; consolidation therapy (also called intensification therapy), which is given once a remission has been achieved to maintain that remission; maintenance therapy, which is given at a lower or less frequent dose to help prolong that remission; first-line therapy (also called standard therapy); second-line (or third-line, fourth-line, etc.) (also called salvage therapy), which is given when the disease has not responded to first-line therapy or when the disease flares up again; and palliative therapy (also called supportive therapy), which addresses symptom management issues without expecting significant reduction in the cancer.
[0068] The terms "preventing" and "prevention" refer to the administration of an agent or composition to a clinically symptomatic individual susceptible to or contracting an adverse condition, disorder or disease, and thus to preventing the onset of symptoms and / or their underlying causes.
[0069] Unless specifically stated or obvious from the context, herein, the term "or" should be understood to be inclusive. Unless specifically stated or obvious from the context, herein, the terms "a", "an" and "the" should be understood to be singular or plural.
[0070] Unless specifically set or obvious from the context, herein, the term "about" should be understood to be within the normal tolerance of the field, for example, within 2 standard deviations of the mean. Approximately can be understood to be within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the set value. Unless the context clearly indicates the opposite, all numerical values provided herein are modified by about.
[0071] Herein, in any definition of a variable, the listing of chemical groups includes the definition of the variable as any single group or combination of the listed groups. Herein, the listing of a specific embodiment of a variable or form includes the specific embodiment as any single specific embodiment or in combination with any other specific embodiment or part thereof.
[0072] Any composition or method provided herein can be used in combination with one or more of any other composition or method provided herein.
[0073] The transitional term "comprising," which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional, uncited elements or method steps. In contrast, the transitional term "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of" limits the scope of the claimed specific materials or steps "and those that do not materially affect the claimed essential and novel characteristics of the invention."
[0074] Other features and advantages of the present invention can be clearly known from the description and claims of the following preferred specific embodiments. Unless excluded by definition, all scientific and technological terms used herein have the same meaning as those generally understood by those skilled in the art. Although methods similar to or equivalent to those disclosed herein can be used to practice or test the present invention, suitable methods and materials are disclosed below. All foreign patent publications and patent applications cited herein are incorporated herein by reference. The gene bank (Genbank) and NCBI submissions indicated by the deposit number cited herein are incorporated herein by reference. All other published references, documents, manuscripts and scientific literature cited herein are incorporated herein by reference. When there is a conflict, the present specification includes definitions. In addition, the materials, methods and embodiments are only illustrative and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figures 1A to 1F A series of line graphs illustrating the effect of ALT-803 on the in vitro proliferation of human immune cell subsets. Human PBMCs were isolated from the buffy coat of blood from two healthy donors (Donor A, Figure 1A , Figure 1C and Figure 1E ; Donor B, Figure 1B , Figure 1D and Figure 1F ) and cultured in RPMI-10 with or without ALT-803 for 5 days ( Figure 1A and Figure 1B ) or mark the time ( Figure 1C , Figure 1D , Figure 1E and Figure 1F ).by Figure 1A and Figure 1B ALT-803 was added at the concentration indicated in the table and 10 nM, and RPMI-10 was used as Figure 1C to Figure 1FThe culture medium control (Ctrl) of the study shown in . At the end of the incubation, PBMCs were stained with fluorescent dye-labeled antibodies specific for CD4, CD8 (as a marker for T cells) and CD16 (as a marker for NK cells). The percentage of cell subsets was analyzed on FACSverse using FACSuite software. Three replicate samples from independent donors were performed Figure 1A and Figure 1B analysis and for each time point a single sample Figure 1C and Figure 1D analysis. Figure 1E and Figure 1F Respectively indicate from Figure 1C and Figure 1D The results obtained were determined from the CD4 / CD8 ratio.
[0076] Figure 2A and Figure 2B Scatter plots showing the effect of ALT-803 on the in vitro proliferation of human immune cell subsets from different donors are shown. Human PBMCs were isolated from buffy coats of blood from 7 healthy donors and cultured for 7 days in pure culture medium or in culture medium containing 0.5 nM IL-15 or ALT-803. At the end of incubation, PBMCs were stained with fluorescent dye-labeled antibodies specific for immune cell subsets and counted. Figure 2A and Figure 2B As shown in , the percentages of cell subsets were analyzed on a FACSverse using FACSuite software and absolute cell counts were calculated.
[0077] Figure 3A , Figure 3B , Figure 3C ,and Figure 3D Figure 2 is a bar graph illustrating the upregulation of CD25 and CD69 molecules on immune cell subsets after incubation with ALT-803. Human PBMCs were isolated from buffy coats of blood from two healthy donors and cultured for 5 days in RPMI-10 with the indicated concentrations of ALT-803. PBMCs activated with ALT-803 were stained with fluorescently labeled antibodies specific for CD4, CD8 (as markers for T cells), CD335 (as marker for NK cells), CD25, and CD69 (as activation markers). CD4 + T cells, CD8 + Fluorescence intensity [geometric mean (MFI)] of CD25 and CD69 expression on T cells and NK cells.
[0078] 4A to 4D This indicates that ALT-803 causes human CD8 +Histogram of upregulated expression of granzyme B and perforin in T cells and NK cells. Human PBMCs were isolated from the buffy coat of blood and cultured for 5 days in RPMI-10 with the indicated concentrations of ALT-803. PBMCs activated with ALT-803 were stained with fluorescent dye-labeled antibodies specific for CD8, CD16, and CD335 (as a marker for NK cells), followed by staining with fluorescent dye-labeled antibodies specific for granzyme B or perforin. CD8 was analyzed on FACSverse using FACSuite software. + T cells ( Figure 4A : Donor 1 and Figure 4C : Donor 2) and NK cells ( Figure 4B : Donor 1 and Figure 4D : Mean fluorescence intensity (MFI: geometric mean) of granzyme B and perforin expression on donor 2).
[0079] Figure 5A , Figure 5B ,and Figure 5C is a series of bar graphs illustrating the effects of ALT-803 on cytokine production and cell proliferation in cultured human and mouse immune cells. Figure 5A ) and mouse spleen cells ( Figure 5B ) were cultured in medium containing the indicated amount of ALT-803 for 4 days. Changes in cytokine secretion during cell culture are shown in Figure 5A and Figure 5B Changes in cell proliferation response based on violet dye dilution are shown in Figure 5C middle.
[0080] FIG. 6A to FIG. 6D is a series of line and bar graphs illustrating the cytotoxicity of human PBMCs induced by ALT-803 against Daudi human B-cell lymphoma and K562 human myeloid leukemia cells. Human PBMCs were used as effector cells and Celltrace purple labeled Daudi cells and K562 cells were used as target cells. Human PBMCs were compared with K562 cells ( Fig. 6A )、Daudi cells( Figure 6B ), or Daudi cells with 10 nM Rituximab (anti-CD20 Ab) ( Figure 6C) were mixed in RPMI-10 with or without 10 nM ALT-803 at the indicated E:T ratios. The cell mixtures were cultured for 3 days at 37°C and the viability of Daudi and K562 target cells was assessed by analysis of propidium iodide staining of purple-labeled target cells on a FACSVerse flow cytometer. Human PBMCs were mixed with purple-labeled K562 or Daudi cells at a 10:1 ratio or with Daudi cells plus Rituximab (ADCC) at a 2:1 ratio in RPMI-10 with or without 10 nM ALT-803. After incubation at 37°C for 1 to 3 days, the % cytotoxicity of target cells ( Fig.6D ).
[0081] Fig. 7A and Figure 7B is a series of line graphs illustrating the concentration-dependent induction of ALT-803 cytotoxicity of human PBMCs against K562 and Daudi cells. Human PBMCs were used as effector cells and Celltrace violet-labeled Daudi cells and K562 cells were used as target cells. Human PBMCs from two donors (A and B) were mixed with violet-labeled K562 cells or Daudi cells at an E:T ratio of 20:1 in RPMI-10 with the indicated concentrations of ALT-803. After incubation for 3 days at 37°C, the viability of Daudi and K562 target cells was assessed by propidium iodide staining analysis of violet-labeled target cells on a FACSVerse flow cytometer.
[0082] FIG. 8A to FIG. 8D is a series of line graphs showing that ALT-803 amplifies ADCC of tumor-specific Ab against tumor cells. Fig. 8A ) or donor 2 ( Figure 8B ) were mixed with purple-labeled CD20-positive Daudi human B-cell lymphoma cells at an E:T ratio of 2:1 in RPMI-10 with the indicated concentrations (0.01 to 10 nM) of ALT-803 alone or with ALT-803 and 10 nM Rituximab (anti-CD20 Ab). After incubation for 2 days at 37°C, the viability of Daudi cells was assessed by propidium iodide staining analysis of purple-labeled target cells on a FACSVerse flow cytometer. In subsequent studies, NK cells were isolated from normal human PBMCs by MACS and used as effector cells. NK cells ( Figure 8C ) and NK-depleted PBMCs ( Fig.8D) were mixed with purple-labeled Daudi cells at an E:T ratio of 1:1 in RPMI-10 containing the indicated concentrations (0.01 or 0.1 nM) of ALT-803 with or without 10 nM Rituximab or HOAT Ab. The cells were incubated at 37°C for 2 days. The viability of Daudi cells was assessed by propidium iodide staining analysis of purple-labeled Daudi cells on a BD FACSVerse.
[0083] Fig. 9A and Fig. 9B The bar graph and line graph show that ALT-803 amplifies ADCC of tumor-specific Ab against tumor cells using mouse spleen cells. Fig. 9A In the studies shown, spleen cells were isolated from tumor-bearing SCID mice treated with PBS, ALT-803 (0.2 mg / kg), Rituximab (10 mg / kg), or ALT-803 + Rituximab. The spleen cells were mixed with Celltrace Purple labeled Daudi cells at an E:T ratio of 20:1 in the presence of medium alone or medium containing ALT-803 (10 nM), Rituximab (10 nM), or ALT-803 + Rituximab. After incubation for 2 days at 37°C, the viability of the Daudi target cells was assessed. Splenocytes were also isolated from Balb / c mice treated with ALT-803 (0.2 mg / kg) Fig. 9B The splenocytes were mixed with Celltrace purple labeled HER2-positive SK-BR-3 human breast cancer cells at an E:T ratio of 10:1 in the presence of medium alone or medium containing various concentrations of anti-HER2 antibody (clone 24D2), ALT-803, or both. After incubation at 37°C for 24 hours, the viability of the SK-BR-3 target cells was assessed.
[0084] Fig.10 Bar graph showing the anti-tumor efficacy of ALT-803 plus anti-CD20 antibody against human B lymphoma in SCID mice. Fox Chase SCID female mice bearing Daudi cell tumors were treated with PBS, ALT-803 (0.2 mg / kg), Rituximab (10 mg / kg), or ALT-803 + Rituximab. Daudi cells in the bone marrow were measured 4 days after the last treatment.
[0085] Fig.11Bar graph showing the anti-tumor efficacy of ALT-803 plus anti-CD20 antibody against human B lymphoma in SCID mice. Fox Chase SCID female mice bearing Daudi cell tumors were treated with PBS, Rituximab, or Rituximab plus various concentrations of ALT-803. Daudi cells in the bone marrow were measured 4 days after the last treatment.
[0086] Fig.12 It is a line graph showing the prolonged survival of mice bearing Daudi cell tumors after ALT-803 plus anti-CD20 Ab therapy. Fox Chase SCID female mice bearing Daudi cell tumors were treated with PBS, Rituximab (10 mg / kg), ALT-803 (0.05 mg / kg), or Rituximab + ALT-803. The survival time of the mice was monitored and Kaplan-Meier survival curves were plotted.
[0087] Fig.13A and Fig. 13B is a series of line graphs showing the prolonged survival of mice bearing CT26 colon cancer lung metastases after ALT-803 and ALT-803 plus anti-CTLA-4 Ab therapy. BALB / c mice bearing CT26 colon cancer lung metastases were treated with PBS, ALT-803, IL-15 monotherapy, and combination therapy with anti-CTLA4 Ab and anti-PD-L1 Ab as noted in the graph. The survival of the mice was monitored and a Kaplan-Meier survival curve was plotted.
[0088] Fig.14A and Fig. 14B is a series of line graphs illustrating the prolonged survival of mice bearing 5T33P myeloma following ALT-803 plus anti-PD-L1 Ab therapy. Fig.14A In the figure, PBS, ALT-803, IL-15 monotherapy and combination therapy with anti-CTLA4 Ab and anti-PD-L1 Ab (0.2 mg / mouse) were used to treat C57BL / 6 mice bearing 5T33P myeloma. The survival time of the mice was monitored and the Kaplan-Meier survival curve was drawn. Fig. 14B In the experiment, PBS, suboptimal ALT-803 (0.05 mg / kg), suboptimal anti-PD-L1 Ab (5 μg), or a combination of ALT-803 + anti-PD-L1 Ab as indicated in the figure were used to treat C57BL / 6 mice bearing 5T33P myeloma. The survival time of the mice was monitored and a Kaplan-Meier survival curve was plotted.
[0089] Fig.15A and Fig. 15Bis a series of graphs showing the expression of ligands for PD1 and CTLA4 on tumor cells. CT26 ( Fig.15A ) and 5T33P( Fig. 15B ) tumor cells and then analyzed using flow cytometer.
[0090] Fig.16A , Fig. 16B , Fig. 16C , Fig.16D , Fig.16E ,and Fig.16F 8 is a series of bar graphs showing changes observed in mice following multiple dose treatment with ALT-803 and post-treatment recovery.
[0091] Fig.17 is a line graph showing the pharmacokinetic profile of ALT-803 in cynomolgus monkeys.
[0092] 18A to 18H is a series of line graphs showing changes in immune cell counts in cynomolgus monkeys treated with multiple doses of ALT-803 and recovered after treatment.
[0093] Fig.19A and Fig.19B is a series of line graphs showing prolonged survival of mice bearing orthotopic MB491uc bladder tumors following ALT-803 plus checkpoint blockade therapy. Fig.19A In the experiment, C57BL / 6 mice bearing orthotopic MB491uc bladder tumors were treated with PBS, ALT-803, and the combination therapy of ALT-803 with anti-CTLA4 Ab and anti-PD-L1 Ab as indicated in the figure. The survival time of the mice was monitored and the Kaplan-Meier survival curve was plotted. After 80 days, the surviving mice in the ALT-803+anti-PD-L1 / anti-CTLA4-Ab group and the untreated mice of the same age were challenged with intracystic administration of MB491uc tumor cells again. The survival of the mice was further monitored. Fig.19B In the present invention, C57BL / 6 mice bearing MB491uc bladder tumors were treated with PBS, ALT-803, anti-PD-1 Ab, anti-CTLA-4 Ab, or combination therapy as indicated in the figure. The survival time of the mice was monitored and the Kaplan-Meier survival curve was drawn.
[0094] Fig. 20 A series of flow cytometric analysis graphs showing the expression of ligands for PD1 and CTLA4 on MB491uc tumor cells. MB491uc tumor cells were stained with antibodies specific for PD-L1, CD86, and CD80 (blue line) or isotype control (black line) and subsequently analyzed using a flow cytometer.
[0095] FIG. 21A to FIG. 21C is a series of line graphs showing the combined effect of ALT-803 and TA99 in a syngeneic murine melanoma model. Fig.21A B16F10 melanoma cells (2 x 10 5 Once palpable tumors were established, mice were randomized to receive intravenous injections of 0.2 mg / kg ALT-803, 10 mg / kg TA99, a combination of ALT-803+TA99, or PBS control on days 10, 14, 17, 21, and 24 of the study. Fig. 21B and Fig. 21C Evaluation of the effect or function of different cell subsets involved in the anti-tumor immunity of the combination therapy was shown. CD4 was injected intraperitoneally with rat mAbs GK1.5 (anti-CD4) and 53.6.72 (anti-CD8a), respectively. + and CD8 + Depletion of T cells. Depletion of NK cells was achieved by intraperitoneal administration of murine mAb PK136 (anti-NK1.1). For depletion of macrophages, mice were injected intraperitoneally with clodronate-loaded liposomes (Clophosomes). Tumor growth ( Fig. 21B ) and mouse survival ( Fig. 21C ) to evaluate the effect of this depletion. Survival curves show the study day when animals died due to tumor metastasis or tumors reaching a threshold size of tumor burden (>20 mm in one dimension). n=8 / group. **: p<0.01; ***: p<0.001.
[0096] FIG. 22A to FIG. 22D is a series of bar graphs illustrating ALT-803 mediated increase in immune cells in the spleen and tumor microenvironment. FIG. 22A to FIG. 22D On day 0 (SD0) of the study, mice (n=6) were injected (subcutaneously) with B16F10 melanoma cells (2 x 10 5 TA99, ALT-803, ALT-803+TA99 combination, or PBS were intravenously injected on SD17. CD8 + T cells (CD8a + )、CD4 + T cells (CD4 + ), NK cells (panNK + ), B cells (CD19 + ), and macrophages (F4 / 80 + ) in spleen cells ( Fig.22A ) and TIL(7-AAD- CD45 + , Fig. 22B ) in percentage. Measure and plot the splenocyte population ( Fig. 22C ) and TIL( Fig.22D ) + CD8 + CD44 高 The percentage of memory T cells.
[0097] FIG. 23A to FIG. 23C is a series of line graphs illustrating that ALT-803+TA99 provides immune protection against tumor challenge. FIG. 23A to FIG. 23B On day 0 (SD0) of the study, B16F10 cells (2 x 10 5 Mice (n=20) were immediately treated with PBS, TA99, or TA99+ALT-803 intravenously. After three weeks of treatment and two months of monitoring, untreated animals and surviving animals were again injected subcutaneously with B16F10 cells (2 x 10 5 Measure and plot the tumor-free animals (animals with subcutaneous tumor volumes maintained at <50 mm) during the initial tumor challenge. 3 )Survival time( Fig.23A ) and tumor growth during re-challenge ( Fig. 23B ). TB = tumor bearing. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Fig.23C On day 58 of the study (SD-58), murine melanoma B16F10 cells (2 x 10 5 100 mg / mouse) was injected subcutaneously into one side of the body of C57BL / 6 mice. Fig.23A The mice were injected with B16F10 cells as shown in the figure, and ALT-803 (0.2 mg / kg) and TA99 (10 mg / kg) were treated with intravenous injection twice a week for three weeks starting from day 0. On day 46 after tumor inoculation, tumor-free mice were intraperitoneally administered with anti-CD4 (GK1.5), anti-CD8 (53-6.72) and / or anti-NK (PK136) to deplete CD4 + T cells, CD8 + To evaluate the anti-tumor memory response of tumor-free mice, B16F10 cells (2 x 10 5 The B16F10 cells were injected subcutaneously into the contralateral side of the body. Untreated naive mice were injected with B16F10 cells as a control. The survival curve summarizes the survival of animals when they died due to tumor metastasis or threshold size (tumor volume > 4000mm 3) and the number of study days when the patient died. n = 10 / group.
[0098] FIG. 24A to FIG. 24E ALT-803 activated CD4 + T cells and upregulate their PD-L1 expression but downregulate CD8 + Graph of PD-1 expression on T cells. On the third day after a single injection of the test substance, the cells were treated with anti-CD25 ( Fig.24A ) or anti-PD-L1( Fig. 24B and Fig.24C ) antibody staining of TIL (7-AAD) from tumor-bearing mice (n=6) - CD45 + ) fraction( Fig.24A and Fig.24C ) and spleen ( Fig. 24B ) + T cells (CD4 + ) and then quantified by flow cytometry. On the third day after a single injection of the test substance, anti-PD-1 ( Fig.24D and Fig.24E ) staining of spleen from tumor-bearing mice (n=6) Fig.24D ) and TIL(7-AAD - CD45 + ) fraction( Fig.24E ) + T cells (CD8 + ; Fig.24D and Fig.24E ), and then quantified by flow cytometry. The expression of PD-L1 and PD-1 was graded using mean fluorescence intensity (MFI). *: p < 0.05; **: p < 0.01; ***: p < 0.001.
[0099] FIG. 25A to FIG. 25D is a series of bar graphs showing that ALT-803 activates NK cells and downregulates PD-1 expression on NK cells. On the third day after a single injection of the test substance, the cells were treated with an anti-KLRG1 antibody ( Fig.25A and Fig.25B ) and anti-PD-1 antibodies ( Fig.25C and Fig.25D ) staining of spleen from tumor-bearing mice (n=6) Fig.25A and Fig.25C ) and TIL(7-AAD - CD45 + ) fraction( Fig.25B and Fig.25D )NK cells (panNK +), and then quantified using a flow cytometer. The expression of KLRG1 and PD-1 was graded using mean fluorescence intensity (MFI). *: p < 0.05; **: p < 0.01; ***: p < 0.001.
[0100] FIG. 26A to FIG. 26B is a series of line graphs showing the combined effect of ALT-803 / TA99 and anti-PD-L1 mAb in syngeneic murine melanoma models. Fig.26A B16F10 melanoma cells (2 x 10 5 Once palpable tumors were established, mice were randomized to receive 0.2 mg / kg ALT-803 (iv) and 10 mg / kg TA99 (iv) with or without 100 μg / mouse of anti-PD-L1 Ab 10F.9G2 (ip) on days 10, 14, 17, 21, and 24 of the study. *: p<0.05; ***: p<0.001. Fig.26B In vitro and in vivo expression of PD-L1 on B16F10 cells is shown. B16F10 cells obtained from in vitro culture (solid line) and tumor-bearing mice (dashed line) were stained with fluorescent dye-labeled anti-PD-L1 antibody (red) and analyzed using flow cytometer. Antibody isotype (black) was included as a negative control. DETAILED DESCRIPTION
[0101] The present invention is based, at least in part, on the surprising discovery that combinations of antibodies and ALT-803, which is a complex of an interleukin 15 (IL-15) super agonist mutant and a dimeric IL-15 receptor alpha / Fc fusion protein, can be used to enhance the immune response against neoplasia (e.g., glioblastoma, prostate cancer, blood cancer, B-cell neoplasms, multiple myeloma, B-cell lymphoma, Hodgkin's lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia, cutaneous T-cell lymphoma, T-cell lymphoma, solid tumors, urothelial / bladder cancer, melanoma, lung cancer, renal cell carcinoma, breast cancer, head and neck cancer, colorectal cancer, and ovarian cancer) or infection (e.g., human immunodeficiency virus infection).
[0102] ALT-803
[0103] ALT-803 comprises an IL-15 mutant with increased ability to bind to IL-2Rβγ and enhanced biological activity (U.S. Pat. No. 8,507,222, incorporated herein by reference). This superagonist mutant of IL-15 is disclosed in a publication (J Immunol 2009 183:3598), as well as patents and pending patent applications (e.g., US 12 / 151,980 and US 13 / 238,925) that have been granted by the U.S. Patent and Trademark Office. The combination of this IL-15 superagonist with a soluble IL-15α receptor fusion protein (IL-15RαSu / Fc) resulted in a protein complex with high potential IL-15 in vitro and in vivo activity (Han et al., 2011, Cytokine, 56:804-810; Xu, et al., 2013 Cancer Res. 73:3075-86; Wong, et al., 2013, Oncolmmunology 2:e26442). This IL-15 superagonist complex (IL-15N72D:IL-15RαSu / Fc) is referred to as ALT-803. Pharmacokinetic analysis showed that the half-life of the complex after intravenous administration to mice was 25 hours. ALT-803 exhibited outstanding antitumor activity against aggressive solid and hematological tumor models in immunocompetent mice. It can be administered as a monotherapy with a dosage regimen of twice weekly or once weekly; or as a combination therapy with an antibody. The anti-tumor response of ALT-803 is also durable. Tumor-bearing mice cured after treatment with ALT-803 are also highly resistant to re-challenge with the same tumor cells, indicating that ALT-803 induces an effective immune memory response against reintroduced tumor cells.
[0104] Interleukin-15
[0105] For effector NK cells and CD8 + Interleukin 15 (IL-15) is an important cytokine for the development, proliferation and activation of memory T cells. IL-15 binds to the IL-15 receptor α (IL-15Rα) and is present on effector cells via the IL-2 / IL-15 receptor β-chain (IL-15Rβγ c ) complex. IL-15 and IL-2 share the IL-15Rβγ c However, IL-2 also supports CD4 + CD25 + FoxP3 + Maintenance of regulatory T (Treg) cells and induction of activated CD8 +These effects may limit the anti-tumor therapeutic activity of IL-2. IL-15 does not share these immune suppressive activities with IL-2. In addition, IL-15 is known to be directional to effector CD8 + IL-15 is the only cytokine that provides anti-apoptotic signaling to T cells. IL-15, administered alone or as a complex with IL-15Rα, has demonstrated potent antitumor activity against established solid tumors in experimental animal models and has therefore been demonstrated to be one of the most promising immunotherapeutic drugs that can potentially cure cancer.
[0106] To promote the clinical development of IL-15-based cancer therapy, it has been demonstrated that the IL-15 mutant (IL-15N72D) has increased biological activity compared to IL-15 (Zhu et al., J Immunol, 183: 3598-3607, 2009). The creation of the IL-15N72D: IL-15RαSu / Fc fusion complex (ALT-803) further improved the pharmacokinetics and biological activity of this IL-15 superagonist (IL-15N72D), so that the superagonist complex has at least 25 times the activity of the natural cytokine in vivo (Han et al., Cytokine, 56: 804-810, 2011).
[0107] Fc domain
[0108] ALT-803 comprises an IL-15N72D:IL-15RαSu / Fc fusion complex. Fusion proteins combining the Fc region of IgG with that of another protein, such as various cytokines and soluble receptors, have been reported (see, e.g., Capon et al., Nature, 337:525-531, 1989; Chamow et al., Trends Biotechnol., 14:52-60, 1996; U.S. Pat. Nos. 5,116,964 and 5,541,087). The prototype fusion protein is a homodimeric protein linked by cysteine residues in the hinge region of the IgG Fc, resulting in a molecule similar to an IgG molecule, but without the heavy chain variant and C H1Domain and light chain. The dimeric nature of the fusion protein containing the Fc domain may have advantages in providing higher-order interactions with other molecules (i.e., bivalent or bispecific binding). Due to structural homology, Fc fusion proteins exhibit in vivo pharmacokinetic patterns comparable to human IgG of similar isotypes. IgG class immunoglobulins are the most abundant proteins in human blood, with a circulating half-life of up to 21 days. In order to extend the circulating half-life of IL-15 or IL-15 fusion protein and / or increase its biological activity, a fusion protein complex containing an IL-15 domain (e.g., ALT-803) has been made, wherein the IL-15 domain is non-covalently bonded to IL-15RαSu, and the IL-15RαSu is covalently linked to the Fc site of the human heavy chain IgG protein.
[0109] The term "Fc" refers to the non-antigen binding fragment of an antibody. This "Fc" may be in monomeric or multimeric form. The original immunoglobulin source of natural Fc is preferably human, and may be any immunoglobulin, but preferably IgG1 and IgG2. Natural Fc is composed of monomeric polypeptides and non-covalent associations, and the monomeric polypeptides may be linked by covalent bonds (i.e., disulfide bonds) into dimer or multimer form. Depending on the class (e.g., IgG, IgA, IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, IgGA2), the number of intermolecular disulfide bonds between monomeric subunits in natural Fc molecules ranges from 1 to 4. An example of natural Fc is a disulfide-bonded dimer obtained from papain digestion of IgG (see, Ellison et al. (1982), Nucleic Acids Res. 10: 4071-9). Herein, the term "native Fc" is a general term for monomeric, dimeric, and multimeric forms. The Fc domain contains binding sites for protein A, protein G, various Fc receptors, and complement proteins.
[0110] In some specific embodiments, the term "Fc variant" refers to a molecule or sequence modified from a native Fc, but still comprises a binding site for the rescue receptor FcRn. International patents WO 97 / 34631 (published on September 25, 1997) and WO 96 / 32478 disclose exemplary Fc variants and interactions with rescue receptors, which are incorporated herein by reference. Therefore, the term "Fc variant" comprises a molecule or sequence humanized from a non-human native Fc. Furthermore, the native Fc comprises removable sites because these sites provide structural features or biological activities that are not required by the fusion molecules of the present invention. Therefore, in certain embodiments, the term "Fc variant" includes molecules or sequences that lack one or more sites or residues of native Fc that affect or are involved in (1) disulfide bond formation, (2) incompatibility with a selected host cell, (3) N-terminal heterogeneity when expressed in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a rescue receptor, (7) antibody-dependent cell-mediated cytotoxicity (ADCC), or (8) antibody-dependent cellular phagocytosis (ADCP). Fc variants are further described in detail below.
[0111] The term "Fc domain" encompasses native Fc and Fc variant molecules and sequences defined above. As with Fc variants and native Fc, the term "Fc domain" includes molecules in monomeric or multimeric form, whether digested from whole antibodies or produced by recombinant genetic engineering or other means.
[0112] Fusion protein complex
[0113] The present invention provides ALT-803, in fact, a protein complex between IL-15N72D and IL-15RαSu / Fc. In certain specific embodiments, the ALT-803 polypeptide can be used as a scaffold for fusion to other protein domains. In such fusion protein complexes, the first fusion protein comprises a first biologically active polypeptide covalently linked to interleukin 15 (IL-15) or a functional fragment thereof; and the second fusion protein comprises a second biologically active polypeptide covalently linked to a soluble interleukin 15 receptor α (IL-15Rα) polypeptide or a functional fragment thereof, wherein the IL-15 domain of the first fusion protein binds to the soluble IL-15Rα domain of the second fusion protein to form a soluble fusion protein complex. The fusion protein complex of the present invention also comprises an immunoglobulin Fc domain or a functional fragment thereof linked to one or both of the first and second fusion proteins. Preferably, the Fc domains linked to the first and second fusion proteins react with each other to form a fusion protein complex. This complex can be stabilized by forming a disulfide bond between the immunoglobulin Fc domains. In certain specific embodiments, the soluble fusion protein complex of the present invention comprises an IL-15 polypeptide, an IL-15 variant or a functional fragment thereof and a soluble IL-15Rα polypeptide or a functional fragment thereof, wherein one or both of the IL-15 and IL-15Rα polypeptides further comprises an immunoglobulin Fc domain or a functional fragment thereof.
[0114] In yet another embodiment, one or both of the first and second biologically active polypeptides comprise antibodies or functional fragments thereof.
[0115] In another embodiment, the antigen for use in the antibody domain comprises a cell surface receptor or ligand.
[0116] In another specific embodiment, the antigen includes a CD antigen, a cytokine or chemokine receptor or ligand, a growth factor receptor or ligand, a tissue factor, a cell adhesion molecule, an MHC / MHC-like molecule, an Fc receptor, a Toll-like receptor, a NK receptor, a TCR, a BCR, a positive / negative co-stimulatory receptor or ligand, a death receptor or ligand, a tumor-associated antigen, or an antigen encoded by a virus.
[0117] As used herein, the term "biologically active polypeptide" or "effector molecule" means an amino acid sequence such as a protein, polypeptide or peptide; a sugar or polysaccharide; a lipid or glycolipid, glycoprotein, or lipoprotein that produces the desired effect discussed herein. Effector molecules also include chemical agents. Effector molecule nucleic acids encoding biologically active or effector proteins, polypeptides, or peptides are also contemplated. Thus, suitable molecules include regulatory factors, enzymes, antibodies, or drugs as well as DNA, RNA, and oligonucleotides. The biologically active polypeptide or effector molecule may be naturally occurring, or it may be synthesized from known components such as by recombinant or chemical synthesis methods and may include heterologous components. The biologically active polypeptide or effector molecule is typically between about 0.1 and 100 KD or greater to about 1000 KD, preferably between about 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 30 and 50 KD, as judged by standard molecular size determination techniques such as centrifugation or SDS-polyacrylamide gel electrophoresis. The desired effects of the present invention include, but are not limited to, for example, forming a fusion protein complex of the present invention with increased binding activity; killing target cells, such as to induce cell proliferation or cell death, initiate immune responses in preventing or treating diseases, or be used as a detection molecule for diagnostic purposes. For this detection, an assay can be used, for example, an assay comprising the sequential steps of culturing cells to allow them to proliferate.
[0118] Covalently linking the effector molecule to the fusion protein complex of the present invention according to the present invention provides a number of significant advantages. The fusion protein complex of the present invention can be manufactured to contain a single effector molecule, including peptides of known structure. In addition, multiple effector molecules can be produced in similar DNA vectors. That is, countless different effector molecules can be linked to the fusion protein complex for identifying infected cells or diseased cells. Furthermore, for therapeutic applications, a DNA expression vector encoding the fusion protein complex can be administered to a subject for in vivo expression of the fusion protein complex, rather than administering the fusion protein complex of the present invention to the subject. This approach avoids the expensive purification steps typically associated with the preparation of recombinant proteins, and avoids the complexity of antigen uptake and processing associated with traditional approaches.
[0119] Note that the components of the fusion proteins and antibodies disclosed herein, such as effector molecule conjugates such as cytokines, chemokines, growth factors, protein toxins, immunoglobulin domains or other biologically active molecules and any peptide linkers, can be organized in almost any fashion, as long as the fusion protein or antibody has the desired function. In particular, if desired, each component of the fusion protein can be separated from another component by at least one appropriate peptide linker sequence. In addition, the fusion protein can include a tag, such as to facilitate modification, identification and / or purification of the fusion protein.
[0120] Pharmacotherapeutic agents
[0121] The present invention provides pharmaceutical compositions comprising ALT-803 as a therapeutic agent. In one aspect, ALT-803 is administered systemically, for example, in a pharmaceutically acceptable buffer such as saline. Preferred routes of administration include, for example, instillation into the bladder, subcutaneous injection, intravenous injection, intraperitoneal injection, intramuscular injection, or intradermal injection to provide a continuous, maintenance level of the composition in the patient. Treatment of human patients or other animals is carried out using a therapeutically effective amount of the therapeutic agent identified herein in a physiologically acceptable carrier. Suitable carriers and their formulations are disclosed, for example, in Remington's Pharmaceutical Sciences, edited by EW Martin et al. The amount of the therapeutic agent to be administered varies depending on the mode of administration, the age and weight of the patient, and the clinical symptoms of the neoplasia or infection. Generally, the amount is within the range of other agents used in the treatment of other diseases associated with neoplasia or infection, but in some instances, lower amounts will be required because of the increased specificity of the compound. The compound is administered in an amount that enhances the subject's immune response or reduces neoplastic cell proliferation, survival or invasiveness as determined by methods known to those skilled in the art. Alternatively, the compound may be administered in an amount that reduces infection by a virus or other pathogen of interest.
[0122] Formulation of pharmaceutical composition
[0123] Administration of ALT-803 for the treatment of neoplasia or infection may be performed by any appropriate means resulting in a concentration of the therapeutic agent combined with the other ingredients sufficient to alleviate, reduce or stabilize the neoplasia or infection. ALT-803 may be included in any suitable amount in any suitable carrier substance, and is generally present in an amount of 1 to 95% by weight based on the total weight of the composition. The composition may be provided in a dosage form suitable for parenteral (e.g., subcutaneous, intravenous, intramuscular, intrathecal, or intraperitoneal) administration routes. The pharmaceutical composition can be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy (20th ed.), compiled by A.R. Gennaro, Lippincott Williams and Wilkins, 2000; and Encyclopedia of Pharmaceutical Technology, compiled by J. Swarbrick and J.C. Boylan, 1988-1999, Marcel Dekker, New York).
[0124] The dosage for humans can be initially determined by extrapolating the amount of the compound used in mice or non-human primates, and the skilled artisan will recognize the principles of variation of dosages for humans relative to animal models in the art. In certain specific embodiments, it is expected that the dosage can vary from about 0.1 μg compound / kg body weight to about 5000 μg compound / kg body weight; or from about 1 μg / kg body weight to about 4000 μg / kg body weight, or from about 10 μg / kg body weight to about 3000 μg / kg body weight. In other specific embodiments, the dosage may be about 0.1, 0.3, 0.5, 1, 3, 5, 10, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 μg / kg body weight. In other embodiments, it is contemplated that the dosage may be in the range of 0.5 μg compound / kg body weight to about 20 μg compound / kg body weight. In other embodiments, the dosage may be about 0.5, 1, 3, 6, 10, or 20 mg / kg body weight. Of course, this treatment strategy is routinely performed, and this dosage may be adjusted up or down based on the results of initial clinical trials and the needs of specific patients.
[0125] In particular embodiments, ALT-803 is formulated in an excipient suitable for parenteral administration. In particular embodiments, ALT-803 is administered at 0.5 μg / kg to about 15 μg / kg (eg, 0.5, 1, 3, 5, 10, or 15 μg / kg).
[0126] For the treatment of bladder cancer, ALT-803 is administered by instillation into the bladder. Instillation methods are known. See, for example, Lawrencia, et al., Gene Ther 8, 760-8 (2001); Nogawa, et al., J Clin Invest 115, 978-85 (2005); Ng, et al., Methods Enzymol 391, 304-13 2005; Tyagi, et al., J Urol 171, 483-9 (2004); Trevisani, et al., J Pharmacol Exp Ther 309, 1167-73 (2004); Trevisani, et al., Nat Neurosci 5, 546-51 (2002)); (Segal, et al., 1975). (Dyson, et al., 2005). (Batista, et al., 2005; Dyson, et al., 2005). In certain embodiments, it is contemplated that the dose of ALT-803 for instillation may vary from about 5 to 1000 μg / dose. In other embodiments, the intravesical dose may be about 25, 50, 100, 200, or 400 μg / dose. In other embodiments, ALT-803 is administered by instillation into the bladder in combination with standard therapeutic agents including mitomycin C or bacillus Calmette-Guérin (BCG).
[0127] The pharmaceutical composition is formulated with suitable excipients to release the therapeutic agent in a controlled manner after administration. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, molecular complexes, nanoparticles, patches, and liposomes.
[0128] Parenteral compositions
[0129] The pharmaceutical composition comprising ALT-803 can be administered parenterally by injection, infusion or implantation (subcutaneous, intravenous, intramuscular, intracapsular, intraperitoneal, etc.) in a dosage form, formulation, or via an appropriate delivery device or containing conventional, non-toxic, pharmaceutically acceptable carriers and adjuvants. The formulation and preparation of such compositions are well known to those skilled in the art of pharmaceutical formulation. The formulation can be found in Remington: The Science and Practice of Pharmacy, supra.
[0130] Compositions comprising ALT-803 for parenteral use may be provided in unit dosage form (e.g., in single-dose ampoules, syringes, or bags), or may be provided in vials containing several doses, to which appropriate preservatives may be added (see below). The composition may be in the form of a solution, suspension, emulsion, infusion device, or delivery device for transplantation, or may be present as a dry powder, which may be reconstituted with water or other appropriate carrier prior to use. In addition to the active agent that reduces or alleviates neoplasia or infection, the composition may also include appropriate parenterally acceptable carriers and / or excipients. The active therapeutic agent may be incorporated into microspheres, microcapsules, nanoparticles, liposomes, etc. for controlled release. In addition, the composition may include suspending agents, solubilizing agents, stabilizers, pH adjusters, tonicity adjusters, and / or dispersing agents.
[0131] As described above, the pharmaceutical composition comprising ALT-803 may be in a form suitable for sterile injection. To prepare such a composition, the appropriate active anti-tumor / anti-infective therapeutic agent is dissolved or suspended in a liquid carrier acceptable for parenteral administration. Among acceptable carriers and solvents, water, water adjusted to an appropriate pH by the addition of an appropriate amount of hydrochloric acid, sodium hydroxide or an appropriate buffer, 1,3-butanediol, Ringer's solution, and isotonic sodium chloride solution and dextrose solution may be used. The aqueous formulation may also contain one or more preservatives (e.g., methyl, ethyl or n-propyl paraben). In instances where one of the compounds is only sparingly soluble or slightly soluble in water, a solubility enhancer or cosolvent may be added, or the solvent may include 10 to 60% w / w propylene glycol, etc.
[0132] The present invention provides a method for treating neoplasia or infectious diseases and / or their lesions or symptoms, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound as provided herein to a subject (e.g., a mammal such as a human). Therefore, one specific embodiment is a method for treating a subject suffering from or susceptible to neoplasia or infectious diseases or their lesions or symptoms. The method includes administering a therapeutic amount of a compound as provided herein to the mammal to treat the disease or its lesions or symptoms, wherein the amount is sufficient to treat the disease or lesion to be treated under certain conditions.
[0133] The methods herein include administering an effective amount of a compound disclosed herein or a composition disclosed herein to the subject (including a subject identified as needing such treatment) to produce a treatment effect. Identifying a subject in need of such treatment is within the scope of the subject's or a healthcare provider's judgment and can be subjective (e.g., assertion) or objective (e.g., measurable by a test or diagnostic method).
[0134] The therapeutic methods of the present invention (including prophylactic treatments) generally comprise administering a therapeutically effective amount of a compound herein, such as a compound as set forth herein, to a subject (e.g., an animal, a human) in need thereof, including a mammal, particularly a human. The treatment will be appropriately administered to a subject, particularly a human, suffering from, having, susceptible to, or at risk of a neoplastic or infectious disease, lesion, or symptom thereof. Determination of these subjects as "at risk" may be made by any objective or subjective determination by diagnostic testing or advocacy of the subject or healthcare provider (e.g., genetic testing, enzyme or protein markers, markers (as defined herein), family history, etc.). ALT-803 can be used to treat any other lesion as long as the treatment requires an increase in an immune response.
[0135] In one embodiment, the present invention provides a method for monitoring the progress of treatment. The method includes determining a diagnostic marker (marker) (e.g., any target, protein or indicator thereof adjusted by the compound described herein, etc.) or a diagnostic measurement (e.g., screening, assay) in a subject suffering from or susceptible to a disease or symptom associated with neoplasia or infection, wherein the subject has been administered a therapeutically effective amount of the compound described herein sufficient to treat the disease or its symptoms. The marker level measured in the method can be compared with the known level of the marker in the normal control or other patient to construct the disease state of the subject. In a preferred embodiment, the second level of the marker in the subject is measured at a time point after the first level is measured, and the two levels are compared to monitor the progression of the disease or the efficacy of the treatment. In certain preferred embodiments, the marker level before treatment in the subject is measured before treatment according to the present invention; subsequently, the marker level before treatment is compared with the marker level in the subject after the start of treatment to determine the efficacy of the treatment.
[0136] Combination therapy
[0137] ALT-803 is preferably administered in combination with an anti-neoplastic or anti-infective therapeutic agent such as an antibody, such as a tumor-specific antibody or an immune checkpoint inhibitor. The antibody and ALT-803 may be administered simultaneously or sequentially. In some specific embodiments, the antibody therapy is an established therapy for disease signs, and the addition of ALT-803 therapy to the antibody regimen improves the therapeutic benefit for the patient. This improvement can be measured as an increase in response for each patient or an increase in response for a patient population.
[0138] Combination therapy may also provide improved responses with lower or less frequent doses of the antibody, leading to a more easily tolerated treatment regimen. As described herein, combination therapy of ALT-803 and an antibody may provide enhanced clinical activity through a variety of mechanisms, including expanded ADCC, ADCP, and / or NK cell, T cell, neutrophil or monocyte levels or immune responses.
[0139] If necessary, ALT-803 is administered in combination with any conventional therapy, including but not limited to surgery, radiation therapy, chemotherapy, protein-based therapy, or biological therapy. Chemotherapeutic drugs include alkylating agents (e.g., platinum-based drugs, tetrazines, aziridines, nitrosoureas, nitrogen mustards), antimetabolites (e.g., antifolates, fluoropyrimidines, deoxynucleotide analogs, thiopurines), antimicrotubule agents (e.g., vinca alkaloids, taxanes), topoisomerase inhibitors (e.g., topoisomerase I inhibitors and topoisomerase II inhibitors), cytotoxic antibiotics (e.g., anthracyclines), and immunomodulatory drugs (e.g., thalidomide and analogs).
[0140] Kit or drug system
[0141] The pharmaceutical composition comprising ALT-803 can be assembled into a kit or pharmaceutical system for treating neoplasia or infection. The kit or pharmaceutical system according to this aspect of the invention comprises a carrier means, such as a box, carton, tube, having one or more containers, such as vials, tubes, ampoules, bottles, syringes or bags, within which are strictly confined. The kit or pharmaceutical system of the invention may also comprise the associated instructions for use of ALT-803.
[0142] Recombinant protein expression
[0143] Generally, the preparation of the fusion protein complexes of the present invention (eg, components of ALT-803) can be performed by the procedures disclosed herein and recognized recombinant DNA techniques.
[0144] Typically, recombinant polypeptides are produced by transforming appropriate host cells using all or part of a nucleic acid molecule encoding the polypeptide or a fragment thereof in an appropriate expression vector. It will be appreciated by those skilled in the art of molecular biology that any of a variety of expression systems may be used to provide the recombinant protein. The precise host cell used is not particularly important for the present invention. In fact, recombinant polypeptides may be produced in any eukaryotic host (e.g., Saccharomyces cerevisiae, insect cells such as Sf21 cells, or mammalian cells such as NIH 3T3, HeLa, COS or preferably CHO cells). These cells can be obtained from a variety of sources (e.g., the American Type Culture Collection, Rockland, Md; see also, e.g., Ausubel et al., Current Protocol in Molecular Biology, New York: John Wiley and Sons, 1997). The choice of transfection method and expression vehicle will depend on the selected host system. Transformation methods are disclosed, for example, in Ausubel et al. (supra); expression vehicles may be selected from those provided in Cloning Vectors: A Laboratory Manual (Pouwels et al., 1985, Supp. 1987).
[0145] There are a variety of expression systems for making recombinant polypeptides. Expression vectors that can be used to produce such polypeptides include, but are not limited to, chromosomal-derived vectors, episomal-derived vectors, and viral-derived vectors, such as vectors derived from bacterial plasmids, vectors derived from bacteriophages, vectors derived from transposons, vectors derived from yeast episomes, vectors derived from insertion elements, vectors derived from yeast chromosomal elements, vectors derived from viruses such as baculovirus, papovavirus such as SV40, vaccinia virus, adenovirus, fowl pox virus, pseudorabies virus, and retrovirus, and vectors derived from combinations thereof.
[0146] Once the recombinant polypeptide is expressed, it is separated using, for example, affinity chromatography. In one embodiment, an antibody (e.g., produced as disclosed herein) cultivated to oppose the polypeptide can be adhered to a column and used to separate the recombinant polypeptide. Before affinity chromatography, the lysis and fractionation of cells with polypeptides can be implemented by standard methods (see, for example, Ausubel et al., supra). Once separated, if necessary, the recombinant protein can be further purified by, for example, high performance liquid chromatography (see, for example, Laboratory Techniques In Biochemistry and Molecular Biology, eds., Work and Burdon, Elsevier, 1980, compiled by Fisher).
[0147] Herein, the biologically active polypeptides or effector molecules of the present invention may include factors such as cytokines, chemokines, growth factors, protein toxins, immunoglobulin domains or other biologically active proteins such as enzymes. The biologically active polypeptides may also include conjugates conjugated to other compounds, such as non-protein toxins, cytotoxic agents, chemotherapeutic agents, detectable labels, radioactive materials, etc.
[0148] The cytokine of the present invention is defined by any factor that affects the cell production of other cells, and the cytokine can respond to any of a large number of cellular immune pleiotropy. Examples of cytokines include, but are not limited to, the IL-2 family, interferon (IFN), IL-10, IL-1, IL-17, TGF and TNF cytokine families, and IL-1 to IL-35, IFN-α, IFN-β, IFNγ, TGF-β, TNF-α and TNFβ.
[0149] In one aspect of the invention, the first fusion protein comprises a first biologically active polypeptide covalently linked to an interleukin-15 (IL-15) domain or a functional fragment thereof. IL-15 is a cytokine that affects T cell activation and proliferation. The IL-15 activity that affects immune cell activation and proliferation is similar to some aspects of IL-2, but the two have fundamental differences (Waldmann, TA, 2006, Nature Rev. Immunol. 6: 595-601).
[0150] In another aspect of the present invention, the first fusion protein comprises an interleukin-15 (IL-15) domain, which is an IL-15 variant (also referred to herein as an IL-15 mutant). The IL-15 variant preferably comprises a different amino acid sequence from the natural (or wild-type) IL-15 protein. The IL-15 variant preferably binds to the IL-15Rα polypeptide and functions as an IL-15 agonist or antagonist. The IL-15 variant with agonist activity preferably has super agonist activity. In some specific embodiments, the IL-15 variant can function as an IL-15 agonist or antagonist that is independent of its association with IL-15Rα. IL-15 agonists are exemplified by biological activities comparable to or relatively increased with wild-type IL-15. IL-15 antagonists are exemplified by biological activity activity reduced than wild-type IL-15 or by the ability to inhibit IL-15-mediated responses. In some embodiments, the IL-15 variant with increased or decreased activity is bound to the IL-15RβγC receptor. In some specific embodiments, the sequence of the IL-15 variant has at least one amino acid change, such as substitution or elimination, compared to the natural IL-15 sequence, which changes the activity of the IL-15 agonist or antagonist. The amino acid substitution / elimination is preferably in the domain of IL-15 that interacts with IL-15Rβ and / or γC. The amino acid substitution / elimination more preferably does not affect the binding to the IL-15Rα polypeptide or the ability to produce the IL-15 variant. Based on the inferred or known IL-15 structure, IL-15 can be compared with homologous molecules such as IL-2 with a known structure, and the appropriate amino acid substitution / elimination for generating the IL-15 variant can be identified through the rational or random mutations and functional tests or other empirical methods provided herein. Other appropriate amino acid substitutions can be conservative or non-conservative changes and insertions of other amino acids. The IL-15 variants of the present invention preferably contain one or more amino acid substitutions / eliminations at positions 6, 8, 10, 61, 65, 72, 92, 101, 104, 105, 108, 109, 111, or 112 of the mature human IL-15 sequence; in particular, D8N ("D8" refers to the position of the amino acid and residue in the native mature human IL-15 sequence, and "N" refers to the substituted amino acid residue position in the IL-15 variant), I6S, D8A, D61A, N65A, N72R, V104P or Q108A substitutions result in IL-15 variants with antagonist activity, while N72D substitutions result in IL-15 variants with agonist activity.
[0151] Chemokines, like cytokines, are defined as any chemical factor or molecule that, when exposed to other cells, responds to any of a number of cellular immune pleiotropy. Suitable chemokines may include, but are not limited to, the CXC, CC, C, and CX.sub.3C chemokine families and CCL-1 to CCL-28, CXC-1 to CXC-17, XCL-1, XCL-2, CX3CL1, MIP-1b, IL-8, MCP-1, and Rantes.
[0152] Growth factors include any molecule that, when exposed to a particular cell, induces proliferation and / or differentiation of the affected cell. Growth factors include proteins and chemical molecules, some of which include: GM-CSF, G-CSF, human growth factor, and stem cell growth factor. Other growth factors may also be suitable for the purposes disclosed herein.
[0153] Toxins or cytotoxic agents include any substance that has a lethal effect or a growth inhibitory effect when exposed to cells. More specifically, the effector molecule can be a cytotoxin such as from a plant or bacterium, such as diphtheria toxin (DT), Shiga toxin, abrin, cholera toxin, ricin, saponin, Pseudomonas exotoxin (PE), pokeweed antiviral protein, or gelonin. Biologically active fragments of these toxins are known in the art and include, for example, DTA chains and ricin A chains. In addition, the toxin can be an agent that is active on the cell surface, such as a phospholipase (e.g., phospholipase C).
[0154] Furthermore, the effector molecule can be a chemotherapeutic drug such as, for example, vindesine, vincristine, vinblastine, methotrexate, doxorubicin, bleomycin, or cisplatin.
[0155] In addition, the effector molecule can be a detectably labeled molecule suitable for diagnostic or imaging studies. Such labels include biotin or streptavidin / avidin, detectable nanoparticles or crystals, enzymes or catalytically active fragments thereof, fluorescent labels such as green fluorescent protein, FITC, phycoerythrin, cychome, Texas Red or quantum dots; radionuclides such as iodine-131, yttrium-90, rhenium-188 or bismuth-212; phosphorescent or chemiluminescent molecules or labels detectable by PET, ultrasound or MRI, such as contrast agents based on Gd or paramagnetic metal ions. See, e.g., Moskaug, et al. J. Biol. Chem. 264, 15709 (1989); Pastan, I. et al. Cell 47, 641, 1986; Pastan et al., Recombinant Toxins as Novel Therapeutic Agents, Ann. Rev. Biochem. 61, 331, (1992); "Chimeric Toxins" Olsnes and Phil, Pharmac. Ther., 25, 355 (1982); PCT Publication WO 94 / 29350; PCT Publication WO 94 / 04689; PCT Publication WO 2005046449; and U.S. Pat. No. 5,620,939 for disclosures related to making and using proteins comprising effector tags.
[0156] Protein fusion or conjugate complexes comprising covalently linked IL-15 and IL-15Rα have several important uses. Cells or tissues susceptible to damage or killing can be readily assayed using the methods disclosed herein.
[0157] The amino acid sequences of the IL-15 polypeptides and IL-15Rα polypeptides of the present invention are appropriately consistent with natural IL-15 molecules and IL-15Rα molecules, such as IL-15 molecules and IL-15Rα molecules of humans, mice or other rodents or other mammals. The sequences of these polypeptides and encoding nucleic acids can be found in the literature, including human interleukin 15 (IL15) mRNA-GenBank: U14407.1; Mus musculus interleukin 15 (IL15) mRNA-GenBank: U14332.1; human interleukin-15 receptor α chain precursor (IL15RA) mRNA-GenBank: U31628.1; Mus musculus interleukin 15 receptor α chain-GenBank: BC095982.1.
[0158] In some settings, it can be used to make multivalent protein fusion or conjugate complexes of the invention, such as to increase the valency of a sc-TCR or sc-antibody. In particular, the reaction between the IL-15 domain and the IL-15Rα domain of the fusion protein complex provides a means for generating a multivalent complex. In addition, the multivalent fusion protein can be made by covalently or non-covalently linking 1 to 4 proteins (same or different) together, such as using standard biotin-streptavidin labeling techniques, or by conjugation to a suitable solid support such as latex microspheres. Chemically cross-linked proteins (e.g., cross-linked to nanoparticles) are also suitable multivalent substances. For example, the protein can be modified by including a sequence encoding a modifiable tag such as a biotinylated BirA tag or a sequence of amino acid residues with chemically reactive side chains such as Cys or His. Such amino acid tags or chemically reactive amino acids can be located at multiple positions in the fusion protein or antibody, preferably distal to the active site of the biologically active polypeptide or effector molecule. For example, the C-terminal of soluble fusion protein can be covalently linked to a tag or other fusion protein comprising this reactive amino acid. Suitable side chains can be included to chemically link two or more fusion proteins to suitable nanoparticles to provide multivalent molecules. Exemplary nanoparticles include dendrimers, liposomes, core-shell particles or particles based on PLGA.
[0159] In another specific embodiment of the present invention, one or both polypeptides of the fusion protein complex comprise an immunoglobulin domain. Alternatively, the protein binding domain-IL-15 fusion protein may be further linked to an immunoglobulin domain. Preferably, the immunoglobulin domain comprises a region as provided above that allows interaction with other immunoglobulin domains to form a multi-chain protein. For example, the immunoglobulin heavy chain region, such as IgG1 C H2 -C H3 , which can stably react with each other to create an Fc region. The immunoglobulin domain that includes the Fc domain preferably also includes a region with effector function, including Fc receptor or complement protein binding activity, and / or has a glycosylation site. In some specific embodiments, the immunoglobulin domain of the fusion protein complex contains a mutation that reduces or amplifies Fc receptor or complement set activity or glycosylation, thereby affecting the biological activity of the resulting protein. For example, an immunoglobulin domain containing a mutation that reduces its binding to an Fc receptor can be used to generate a fusion protein complex of the present invention, which has a low binding activity to an Fc receptor, which may be useful for reagents designed to recognize or detect specific antigens.
[0160] Nucleic acids and vectors
[0161] The present invention further provides nucleic acid sequences and specific DNA sequences encoding proteins of the present invention (e.g., components of ALT-803). Preferably, the DNA sequence is carried by a vector suitable for extrachromosomal replication, such as a phage, virus, plasmid, phagemid, cosmid, YAC, or episome. In particular, DNA vectors encoding the desired fusion protein can be used to facilitate the preparative methods disclosed herein and to obtain significant quantities of the fusion protein. The DNA sequence can be inserted into a suitable expression vector, i.e., a vector containing the necessary elements for transcription and translation of the inserted protein coding sequence. A variety of host-vector systems can be used to express the protein coding sequence. These include mammalian cell systems infected with viruses (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with viruses (e.g., baculovirus); microorganisms such as yeast vectors containing yeast, or bacteria transformed with phage DNA, plasmid DNA, or cosmid DNA. Depending on the host-vector system employed, any of a number of appropriate transcription and translation elements can be used. See, Sambrook et al., supra, and Ausubel et al., supra.
[0162] The present invention includes a method for making a soluble fusion protein complex, which comprises introducing the DNA vector encoding the first and second fusion proteins disclosed herein into a host cell; culturing in a culture medium under conditions sufficient to express the fusion proteins in the cell, or culturing in the culture medium under conditions that allow the IL-15 domain of the first fusion protein to associate with the soluble IL-15Rα domain of the second fusion protein to form a soluble fusion protein complex; and purifying the soluble fusion protein complex from the host cell or the culture medium.
[0163] Generally, the DNA vector according to the present invention preferably comprises a nucleotide sequence linked by a phosphodiester bond, which comprises, in the 5′ to 3′ direction, a first cloning site for introducing a first nucleotide sequence encoding a biologically active polypeptide, operably linked to a sequence encoding an effector molecule.
[0164] The fusion protein components encoded by the DNA vector can be provided in a cassette format. The term "cassette" means that each component can be easily replaced by another component by standard recombination methods. In particular, when the encoded fusion complex is to be used against pathogens that may have or have the ability to develop serotypes, DNA vectors configured in a cassette format are particularly desirable.
[0165] In order to make the vector encode the fusion protein complex, the sequence encoding the biologically active polypeptide is linked to the sequence encoding the effector peptide using an appropriate ligase. DNA encoding the existing peptide can be obtained by isolating DNA from a natural source, such as from an appropriate cell, or by a known synthetic method, such as the phosphotriester method. See, e.g., Oligonucleotide Synthesis, IRL Press (MJ Gait, ed., 1984). Synthetic oligonucleotides can also be prepared using a commercially available oligonucleotide synthesizer. Once isolated, the gene encoding the biologically active polypeptide can be amplified by polymerase chain reaction (PCR) or other means known in the art. Appropriate PCR primers for amplifying the biologically active polypeptide gene can add restriction sites to the PCR product. The PCR product preferably includes a splice site for the effector peptide, and a leader sequence necessary for the appropriate expression and secretion of the biologically active polypeptide-effector fusion complex. The PCR product also preferably includes a sequence encoding the linker sequence, or a restriction enzyme site for ligating the sequence.
[0166] The fusion proteins disclosed herein are preferably produced by standard recombinant DNA techniques. For example, once the DNA molecule encoding the biologically active polypeptide is isolated, the sequence can be ligated to another DNA molecule encoding the effector polypeptide. The nucleotide sequence encoding the biologically active polypeptide can be directly joined to the DNA sequence encoding the effector peptide, or, more typically, the DNA sequence encoding the linker sequence discussed herein can be inserted between the sequence encoding the biologically active polypeptide and the mainstream encoding the effector peptide and joined using an appropriate ligase. The resulting hybrid DNA molecule can be expressed in an appropriate host cell to produce a fusion protein complex. The DNA molecules are ligated to each other in a 5' to 3' orientation, so that after ligation, the translation frame of the encoded polypeptide is not changed (i.e., the DNA molecules are ligated to each other in frame). The resulting DNA molecule encodes an in-frame fusion protein.
[0167] Other nucleotide sequences may also be included in the gene construct. For example, a promoter sequence, which controls the expression of a sequence encoding a biologically active polypeptide fused to an effector peptide, or a leader sequence, which directs the fusion protein to the cell surface or culture medium, may be included in the construct or present in an expression vector into which the construct is inserted. Immunoglobulin or CMV promoters are particularly preferred.
[0168] In obtaining variant biologically active polypeptides, IL-15, IL-15Rα or Fc domain encoding sequences, one skilled in the art will recognize that polypeptides may be modified by substitution, addition, elimination, and post-translational modification of certain amino acids without loss or reduction of biological activity. In particular, it is known that conservative amino acid substitutions, i.e., substitution of one amino acid for another amino acid of similar size, charge, polarity, and conformation, are unlikely to significantly alter protein function. Broadly speaking, the 20 standard amino acids that serve as building blocks of proteins are divided into four groups of conservative amino acids as follows: a nonpolar (hydrophobic) group, including alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine; a polar (uncharged, neutral) group, including asparagine, cysteine, glutamine, glycine, serine, threonine, and tyrosine; a positively charged (basic) group, containing arginine, histidine, and lysine; and, a negatively charged (acidic) group, containing aspartic acid and glutamic acid. The substitution of one amino acid in a protein for another amino acid in the same group is unlikely to have a negative impact on the biological activity of the protein. In other examples, modifications can be made to the amino acid positions to reduce or enhance the biological activity of the protein. These changes can be introduced randomly or through site-specific mutagenesis based on the known or inferred structural or functional properties of the targeted residues. After the variant protein is expressed, the changes in biological activity caused by the modification can be easily assessed using binding or functional assays.
[0169] Homology between nucleotide sequences can be determined by DNA hybridization separation, wherein the stability of double-stranded DNA hybrids depends on the degree of base pairing that occurs. Conditions of high temperature and / or low salt content reduce the stability of the hybrids, and conditions can be altered to prevent annealing of sequences with homology below a selected degree. For example, for sequences having a GC content of about 55%, hybridization and washing conditions of 40 to 50°C, 6 x SSC (sodium chloride / sodium citrate buffer) and 0.1% SDS (sodium dodecyl sulfate) indicate about 60 to 70% homology; hybridization and washing conditions of 50 to 65°C, 1 x SSC and 0.1% SDS indicate about 82 to 97% homology; and hybridization and washing conditions of 52°C, 0.1 x SSC and 0.1% SDS indicate about 99 to 100% homology. A large number of computer programs for comparing nucleotide and amino acid sequences (and measuring the degree of homology) are also available, and a list of both commercially available and free software sources can be found in Ausubel et al. (1999). Readily available sequence comparison and multiple sequence alignment algorithms are the Basic Local Alignment Search Tool (BLAST) (Altschul et al., 1997) and the ClustalW program, respectively. BLAST is available at www.ncbi.nlm.nih.gov, and a version of ClustalW is available at 2.ebi.ac.uk.
[0170] The components of the fusion protein can be organized in almost any order, as long as each can perform its intended function. For example, in one embodiment, the biologically active polypeptide is located at the C-terminus or N-terminus of the effector molecule.
[0171] The effector molecules of the invention will preferably have a size that is beneficial to the intended function of those domains. The effector molecules of the invention can be made and fused to the biologically active polypeptide by a variety of methods, including well-known chemical cross-linking methods. See, e.g., Means, GE and Feeney, RE (1974), Chemical Modification of Proteins, Holden-Day. See also, SS Wong (1991), Chemistry of Protein Conjugation and Cross-Linking, CRC Press. However, it is generally preferred to use recombinant techniques to make the in-frame fusion protein.
[0172] Note that the fusion molecules or conjugate molecules according to the present invention can be organized in a variety of ways. In an exemplary configuration, the C-terminus of the biologically active polypeptide is operatively linked to the N-terminus of the effector molecule. If desired, the linking can be achieved by recombinant methods. However, in another configuration, the N-terminus of the biologically active polypeptide is linked to the C-terminus of the effector molecule.
[0173] Alternatively or in addition, if desired, one or more additional effector molecules may be inserted into the biologically active polypeptide or conjugate.
[0174] Vectors and expression
[0175] A number of strategies may be employed to express ALT-803. For example, a construct encoding ALT-803 may be incorporated into an appropriate vector using restriction enzymes to create a segment within the vector for insertion of the construct after ligation. The vector containing the gene construct is then introduced into an appropriate fusion protein expression host. See, generally, Sambrook et al., supra. The selection of an appropriate vector may be made based on factors associated with the cloning strategy. For example, the vector should be compatible with the host to be employed and have a replicon suitable for the latter. The vector must be capable of receiving the DNA sequence encoding the fusion protein complex to be expressed. Suitable host cells include eukaryotic and prokaryotic cells, preferably those that are easily transformed and exhibit rapid growth in culture. In particular, preferred host cells include prokaryotes such as Escherichia coli, Bacillus subtilis, and the like, as well as eukaryotic cells such as animal cells and yeast strains such as Saccharomyces cerevisiae. Mammalian cells are generally preferred, particularly J558, NSO, SP2-0 or CHO. Other suitable hosts include, for example, insect cells such as Sf9. Conventional culture conditions are employed. See, Sambrook, supra. Subsequently, an appropriate transformed or transfected cell line may be selected. Cells expressing the fusion protein complex of the invention may be detected by known procedures. For example, expression of the fusion protein complex linked to an immunoglobulin may be detected by an ELISA specific for the linked immunoglobulin and / or by immunoblotting. Other methods of detecting expression of a fusion protein comprising a biologically active polypeptide linked to an IL-15 or IL-15Rα domain are disclosed in the embodiments.
[0176] As generally described above, host cells can be used for preparative purposes to propagate nucleic acids encoding desired fusion proteins. Thus, host cells can include prokaryotic cells or eukaryotic cells in which it is desired that the fusion protein is specifically produced. Thus, host cells specifically include yeast, flies, insects, plants, frogs, mammalian cells and organs capable of propagating nucleic acids encoding the fusion protein. Non-limiting examples of mammalian cell lines used include CHO dhff cells (Urlaub and Chasm, Proc. Natl. Acad. Sci. USA, 77: 4216 (1980)), 293 cells (Graham et al., J Gen. Virol, 36: 59 (1977)) or myeloma cells like SP2 or NSO (Galfre and Milstein, Meth. Enzymol., 73 (B): 3 (1981)).
[0177] Host cells capable of propagating the desired fusion protein complex also encompass non-mammalian eukaryotic cells, including insects (e.g., Spodoptera frugiperda), yeast (e.g., Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, Kluyveromyces lactis, Hansenula polymorpha; generally reviewed by Fleer, R. in Current Opinion in Biotechnology, 3(5):486496 (1992)), fungi, and plant cells. Certain prokaryotes such as Escherichia coli and Bacillus are also contemplated.
[0178] Nucleic acid encoding the desired fusion protein can be introduced into host cells by standard techniques for transfecting cells. The term "transfection" or "transfection" is intended to encompass all conventional techniques for introducing nucleic acid into host cells, including calcium phosphate coprecipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, microinjection, viral transduction and / or integration. Suitable methods for transfecting host cells can be found in Sambrook et al., supra, and other laboratory manuals.
[0179] Various promoters (transcription initiation regulatory regions) can be used according to the present invention. The appropriate promoter is selected depending on the proposed expression host. Promoters from heterologous sources can be used as long as they function in the selected host.
[0180] The selection of promoter also depends on the desired efficacy and the level of peptide or protein production. Generally, inducible promoters such as tac are used to dramatically increase the level of protein expression in E. coli. Overexpression of protein may be harmful to the host cell. Therefore, the growth of the host cell may be limited. Using an inducible promoter system allows the host cell to be cultivated to have an acceptable density before inducing gene expression, thereby facilitating a higher yield.
[0181] Various signal sequences can be used according to the present invention. A signal sequence of the same species as the biologically active polypeptide encoding sequence can be used. Alternatively, a signal sequence that has been selected or designed to be effectively secreted and processed in an expression host can also be used. For example, appropriate signal sequence / host cell pairs include the Bacillus subtilis sacB signal sequence for secretion in Bacillus subtilis, and the Saccharomyces cerevisiae α-mating factor or Pichia pastoris acid phosphatase phoI signal sequence for secretion in Pichia pastoris. The signal sequence can be directly connected to the protein coding sequence by a sequence encoding the signal peptidase cleavage site, or by a short nucleotide bridge that is generally less than 10 codons, wherein the bridge ensures the correct reading frame of the downstream protein sequence.
[0182] Elements for increasing transcription and translation have been identified for use in eukaryotic protein expression systems. For example, placing 1000 bp of the cauliflower mosaic virus (CaMV) promoter on either side of a heterologous promoter can increase transcription levels in plant cells by 10 to 400 fold. The expression construct should also include a suitable translation initiation sequence. Modifying the expression construct to include a Kozak consensus sequence for appropriate translation initiation can increase translation levels by 10 fold.
[0183] A selectable marker is generally used and can be part of the expression construct or separate from the latter (e.g., carried by the expression vector) so that the marker can be incorporated at a site different from the gene of interest. Examples include markers that confer resistance to antibiotics (e.g., bla for ampicillin resistance in E. coli, nptII for kanamycin resistance in a variety of prokaryotes and eukaryotic cells), or markers that allow the host to grow in animal culture (e.g., HIS4 marker for Pichia pastoris or His - Saccharomyces cerevisiae grows in the absence of histidine). The selectable marker has its own transcription and translation initiation and termination regulatory regions to allow independent expression of the marker. If antibiotic resistance is used as a marker, the antibiotic concentration used for selection will vary depending on the type of antibiotic, generally ranging from 10 to 600 μg of antibiotic / mL culture medium.
[0184] The expression construct is assembled by using known recombinant DNA technology (Sambrook et al., 1989; Ausubel et al., 1999). Restriction enzyme digestion and ligation are the basic steps used to combine the two fragments of DNA. The two ends of the DNA fragment may need to be modified before ligation, which can be completed by filling the overhang, using nuclease (such as ExoIII) to eliminate the terminal part of the fragment, site-directed mutagenesis, or adding new base pairs by PCR. Multiplexers and adapters can be used to facilitate the joining of selected fragments. Typically, the expression construct is assembled in stages using a cycle of restriction, ligation, and transformation of Escherichia coli. A large number of cloning vectors suitable for the construction of the expression construct are known in the art (λZAP and pBLUESCRIPTSK-1, Stratagene, La Jolla, CA, pET, Novagen Inc., Madison, WI, cited in Ausubel et al., 1999), and specific selection is not critical to the present invention. The choice of cloning vector will be influenced by the gene transfer system chosen to introduce the expression construct into the host cell. At the end of each stage, the resulting construct can be analyzed by restriction analysis, DNA sequence analysis, hybridization analysis, and PCR analysis.
[0185] The expression construct can be transferred into the host as a cloning vector construct, either linear or circular, or can be removed from the cloning vector and used directly or introduced into a delivery vector. The delivery vector facilitates the introduction of the expression construct into the selected host cell type and the maintenance of the former in the latter. The expression construct is introduced into the host cell by any of a number of known gene transfer systems (e.g., natural competence, chemically mediated transformation, protoplast transformation, electroporation, gene gun transformation, transfection, or conjugation) (Ausubel et al., 1999; Sambrook et al., 1989). The gene transfer system is selected based on the host cell and vector system used.
[0186] For example, the expression construct can be introduced into Saccharomyces cerevisiae cells by protoplast transformation or electroporation. Electroporation of Saccharomyces cerevisiae can be easily accomplished, and the efficiency of yeast transformation is comparable to that of spheroplast transformation.
[0187] The present invention further provides a production process for separating the fusion protein of interest. In the process, the nucleic acid encoding the protein of interest and effectively linked to the regulatory sequence is introduced into the host cell (such as yeast, fungi, insects, bacteria or animal cells) therein, and the transcription of the nucleotide sequence of the protein of interest is stimulated by growth in the culture medium on a production scale. Subsequently, the fusion protein of interest is separated from the host cell of the harvest or isolated from the culture medium. Standard protein purification techniques can be used to separate the protein of interest from the cell of the culture medium or the harvest. In particular, the purification technique can be used to express and purify the desired fusion protein on a large scale in actual apparatus, and the actual apparatus includes a roller bottle, a stirred bottle reactor, a tissue culture plate, a bioreactor or a fermenter.
[0188] The expressed protein fusion complex can be separated and purified by known methods. Typically, the culture medium is centrifuged or filtered, and the supernatant is then purified by affinity chromatography or immunoaffinity chromatography, such as protein-A or protein-G nucleophilic chromatography, or an immunoaffinity scheme comprising the use of a monoclonal antibody that binds to the expressed fusion complex. The fusion protein of the present invention can be separated and purified by a suitable combination of known techniques. These methods include, for example, methods using solubility, such as salt precipitation and solvent precipitation; methods using molecular weight differences, such as dialysis, ultrafiltration, gel filtration, and SDS-polyacrylamide gel electrophoresis; methods using charge differences, such as ion exchange column chromatography; methods using specific affinity, such as affinity chromatography; methods using hydrophobicity differences, such as reversed-phase high performance liquid chromatography; and methods using isoelectric point differences, such as isoelectric focusing electrophoresis, metal affinity columns such as Ni-NTA. See generally the disclosure of these methods in Sambrook et al. and Ausubel et al. above.
[0189] Preferably, the fusion protein of the present invention is substantially pure. That is, the fusion protein has been separated from its naturally associated cellular replacement, so the fusion protein is preferably present at least 80% or 90% to 95% homogeneity (w / w). Fusion proteins with a homogeneity (w / w) of at least 98 to 99% are most preferred for most pharmaceutical, clinical and research applications. For therapeutic applications, substantially pure fusion monomers should be substantially free of impurities. Once purified to partial or general purity, the soluble fusion protein can be used for therapeutic purposes, or for conducting in vitro and in vivo assays, as disclosed herein.
[0190] Substantial purity can be determined by a variety of standard techniques, such as chromatography and gel electrophoresis.
[0191] The fusion protein complexes of the present invention are suitable for use in vitro or in vivo in a variety of cancerous cells or infected cells or cells that may be infected by one or more diseases.
[0192] Human interleukin-15 (hIL-15) is translocated to immune effector cells via the human IL-15 receptor α chain (hIL-15Rα) expressed on antigen presenting cells. IL-15Rα binds hIL-15 with high affinity (38 pM) primarily through the extracellular sushi domain (IL-15RαSu). As described herein, the IL-15 and IL-15RαSu domains can be used to generate soluble complexes (e.g., ALT-803) or as scaffolds to construct multi-domain fusion complexes.
[0193] IgG domains, and in particular the Fc fragment, have been successfully used as dimer scaffolds in a number of therapeutic molecules, including approved biologic drugs. For example, etanercept is a dimer of the soluble human p75 tumor necrosis factor alpha (TNF-α) receptor (sTNFR) linked to the Fc domain of human IgG1. This dimerization gives etanercept the potential to inhibit TNF-α activity up to 1,000-fold that of monomeric sTNFR and provides the fusion with a serum half-life that is five times longer than the monomeric form. As a result, etanercept is effective in neutralizing the pro-inflammatory activity of TNF-α in vivo and improving patient recovery from a number of different autoimmune indications.
[0194] In addition to its dimerization activity, the Fc fragment also provides cytotoxic effector functions by complement activation and interaction with Fcγ receptors expressed on natural killer (NK) cells, neutrophils, monocytes, phagocytes and dendritic cells. In the context of anti-cancer therapeutic antibodies and other antibody domain-Fc fusion proteins, these activities seem to play an important role in the efficacy observed in animal tumor models and cancer patients. However, in a large number of therapeutic applications, these cytotoxic effector responses may not be enough. Therefore, improving and expanding the effector activity of the Fc domains and developing other activities or supplements that increase the cytolytic immune response have received extensive attention, and the immune response includes NK cells and T cells in the disease site via immunotherapeutic molecules.
[0195] In an attempt to develop human immunostimulatory therapeutics, human IL-15 (hIL-15) and the IL-15 receptor domain were used. hIL-15 is a member of the small four-alpha-helical bundle family of cytokines that binds to IL-15 with high binding affinity (equilibrium dissociation constant (KD) ~10 -11M). The resulting complex then in turn appears on the human IL-2 / 15 receptor β / common γ chain (hIL-15RβγC) complex displayed on the surface of T cells and NK cells. This cytokine / receptor interaction leads to the expansion and activation of effector T cells and NK cells, which play an important role in eradicating virally infected cells and malignant cells. Under normal circumstances, hIL-15 and hIL-15Rα are produced simultaneously in dendritic cells to form an intracellular complex, which is then secreted and displayed on the cell surface as a heterodimeric molecule. Therefore, the characteristics of the interaction between hIL-15 and hIL-15Rα suggest that these intermediate chain binding domains can be used as human immunostimulatory complexes and as scaffolds to make soluble dimeric molecules capable of target-specific binding.
[0196] Unless expressly excluded, the practice of the present invention employs conventional techniques of molecular biology, microbiology, cell biology, biochemistry and immunology (including recombinant techniques), which are within the capabilities of a person skilled in the art. These techniques are fully explained in the literature, such as Molecular Cloning: A Laboratory Manual, second edition (Sambrook, 1989); Oligonucleotide Synthesis (Gait, 1984); Animal Cell Culture (Freshney, 1987); Methods in Enzymology; Handbook of Experimental Immunology (Weir, 1996); Gene Transfer Vectors for Mammalian Cells (Miller and Calos, 1987); Current Protocols in Molecular Biology (Ausubel, 1987); PCR: The Polymerase Chain Reaction, (Mullis, 1994); Current Protocols in Immunology (Weir, 1996); Immunology (Coligan, 1991)). These techniques are applicable to the production of polynucleotides and polypeptides of the present invention, and, as such, can be considered to make and practice the present invention. Techniques particularly useful for specific embodiments are discussed below.
[0197] The following examples are put forward so as to provide those skilled in the art with a complete disclosure and description of how to make and use the assays, screening and therapeutic methods of the invention and are not intended to limit the scope of what the inventors regard as their invention.
[0198] Example
[0199] Example 1: Induction of lymphocyte proliferation and activation by ALT-803
[0200] Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats from healthy subjects using Histopaque-1077. The cells were incubated at 37°C with 5% CO 2The PBMCs were cultured in RPMI-10 medium (RPMI-1640, 2-mercaptoethanol, penicillin-streptomycin-glutamine, non-essential amino acids, sodium pyruvate, and 10% fetal bovine serum) with various amounts of ALT-803. "ALT-803" refers to a complex comprising IL-15N72D non-covalently associated with a dimeric IL-15RαSu / Fc fusion protein, wherein the complex exhibits immunostimulatory activity. Optionally, the IL-15N72D and / or IL-15RαSu / Fc fusion protein comprises 1, 2, 3, 4 or more amino acid changes relative to a reference sequence. An exemplary IL-15N72D amino acid sequence is provided below (see, e.g., U.S. Pat. No. 13 / 769,179, incorporated herein by reference).
[0201] An exemplary IL-15N72D nucleic acid sequence is provided below (with a leader peptide) (SEQ ID NO: 1):
[0202] (Leader peptide)
[0203]
[0204] (IL-15N72D)
[0205]
[0206] (Stop codon)
[0207]
[0208] An exemplary IL-15N72D amino acid sequence is provided below (with a leader peptide) (SEQ ID NO: 2):
[0209] (Leader peptide)
[0210]
[0211] (IL-15N72D)
[0212]
[0213] In some instances, the leader peptide is cleaved from the mature IL-15N72D polypeptide (SEQ ID NO: 3):
[0214] (IL-15N72D)
[0215]
[0216] An exemplary IL-15RαSu / Fc nucleic acid sequence (with leader peptide) is provided below (SEQ ID NO: 4):
[0217] (Leader peptide)
[0218]
[0219] (IL-15RαSu)
[0220]
[0221] (IgG1 CH2-CH3 (Fc domain))
[0222]
[0223]
[0224] (Stop codon)
[0225]
[0226] An exemplary IL-15RαSu / Fc amino acid sequence (with leader peptide) is provided below (SEQ ID NO: 5):
[0227] (Leader peptide)
[0228]
[0229] (IL-15RαSu)
[0230]
[0231] (IgG1 CH2-CH3 (Fc domain))
[0232]
[0233] In some cases, the mature IL-15RαSu / Fc protein lacks the leader sequence (SEQ ID NO: 6):
[0234] (IL-15RαSu)
[0235]
[0236]
[0237] (IgG1 CH2-CH3 (Fc domain))
[0238]
[0239] To assess lymphocyte subset proliferation and activation, ALT-803-treated cells were stained with a combination of Brilliant Violet 510-anti-CD4, PECY7-anti-CD8, and Brilliant Violet 421-anti-CD16 antibodies for surface markers and FITC-anti-granzyme B antibodies for intracellular staining; or with a combination of Brilliant Violet-anti-CD4, PE-anti-CD8, PECY7-anti-CD335, PerCP-CY5.5-anti-CD69, and APC-anti-CD25 antibodies for surface markers and FITC-anti-perforin antibodies for intracellular staining. For intracellular staining, cells were fixed with fixation buffer (PBS containing 2% paraformaldehyde) and incubated at room temperature for 20 minutes. Fixed cells were permeabilized with permeabilization buffer (PBS containing 0.1% saponin and 0.05% sodium azide) and stained with FITC-labeled antibodies specific for human granzyme B or perforin. CD4 was analyzed using FACSuite software on the FACSVerse flow cytometer + T cells, CD8 + T cells and CD16 + The percentage of NK cells in PBMCs activated by ALT-803 and the expression of CD25 activation marker and CD69 activation marker in CD4 + T cells, CD8 + T cells and CD335 + Expression on NK cells.
[0240] CD4 in human PBMCs from different donors after 5 days of incubation in medium containing 0.01 to 10 nM ALT-803 compared to medium control + T cells, CD8 + There were no significant changes in the percentages of T cells or NK cells ( Figure 1A and Figure 1B ). As previous studies have shown that ALT-803 can promote the proliferation response of human PMBC in vitro, the incubation time was extended to increase the sensitivity of this assay. Figure 1C (Donor A) and Figure 1D As shown in (Donor B), after 7 days of culture in the presence of 10 nM ALT-803, CD4+ T cells in PBMC cultures were significantly increased compared to that observed in cells incubated in the absence of ALT-803. + The percentage of T cells decreased, while CD8 + The percentage of T cells increased. This finding was more evident when the CD4 / CD8 ratio was analyzed ( Figure 1E : Donor A; Figure 1F: Donor B). There was no significant difference in the percentage of NK cells in PBMC cultures after incubation for up to 10 days in the presence or absence of ALT-803 ( Figure 1C and Figure 1D ).
[0241] The in vitro effects of ALT-803 and IL-15 on the proliferation of human immune cell subsets from different donors were compared. Addition of 0.5 nM ALT-803 or 0.5 nM IL-15 to human PBMC cultures resulted in an approximately 2-fold increase in lymphocyte counts after 7 days of incubation. + In terms of the absolute numbers of T cell subsets and NK cell subsets, ALT-803 and IL-15 have comparable potential ( Figure 2A and Figure 2B ). ALT-803 also significantly increased CD4 + IL-15 increased the absolute counts of T cells, while IL-15 increased the absolute counts of Treg cells.
[0242] In addition, to understand the immunostimulatory effects of ALT-803, the expression of activation markers CD25 and CD69 on immune cell subsets was examined. FIG. 3A to FIG. 3D As shown, in vitro treatment with ALT-803 can + T cells, CD8 + T cells and NK cells increased CD25 expression in a concentration-dependent manner. + Compared with that seen on T cells or NK cells, CD25 upregulation achieved by ALT-803 was more pronounced on CD4 + The most significant effect was on T cells. + In contrast to CD25, ALT-803 incubation resulted in a significant upregulation of CD69 expression on NK cells, whereas ... + CD69 expression by T cells showed no therapeutic effect or only a very weak therapeutic effect.
[0243] Studies were also conducted to evaluate whether ALT-803 can induce NK cells and CD8 + T cells express higher levels of granzymes and perforins, which play a role in cytolytic responses. Human PBMCs were activated in vitro using ALT-803 as described above, followed by Ab staining to distinguish CD8 + T cell subsets and NK cell subsets were then intracellularly stained using FITC-labeled antibodies specific for human granzyme B or perforin. 4A to 4D As shown, ALT-803 can pass through CD8 + T cells ( Figure 4A and Figure 4C ) and NK cells ( Figure 4B and Figure 4D ) upregulated the expression of granzyme B and perforin in a concentration-dependent manner. In addition, ALT-803 mediated the induction of CD8 + Granzyme B expression in both T and NK cells had a more pronounced effect than ALT-803-mediated perforin expression. These findings are consistent with the concept that ALT-803-induced granzyme B and / or perforin expression may play a role in enhancing the cytotoxicity of PBMCs after incubation with ALT-803.
[0244] Additional studies were performed to compare the effects of ALT-803 on human and murine immune cells. Previous studies have shown that the immunostimulatory effects of proteins on human PBMCs vary significantly depending on whether the protein is present in aqueous or immobilized form. Therefore, cytokine release and proliferation assays for human and murine cells were performed using ALT-803 as a soluble protein or as a plastic-immobilized wet or air-dried preparation. ALT-803 was tested at 0.08, 0.8, and 44 nM, corresponding to maximum serum concentrations of 0.3, 3.0, and 170 μg / kg for human intravenous doses, respectively. For proliferation assays, the Celltrace TM Purple (Invitrogen) labeled with CD3 + T cell enrichment columns, R&D Systems) for human PBMC and mouse CD3 + Cells were cultured in wells containing PBS or ALT-803. As a positive control, 27 nM anti-CD3 Ab (145-2C11 for mouse splenocytes and OKT3 for human PBMCs) was added to separate wells of the same assay format. The cells were incubated for 4 days and then analyzed using a flow cytometer to determine cell proliferation based on violet dye dilution. In addition, as described above, human and mouse immune cells were cultured for 24 and 48 h, and cytokines released into the culture medium were measured using the human and mouse Th1 / Th2 / Th17 flow cytometric bead microarray cytokine kit according to the manufacturer's instructions (BD Biosciences). For immune cell subset analysis, human PBMCs were cultured in various concentrations of ALT-803 or IL-15 and stained with CD4, CD8, CD335, CD16, or CD19 specific antibodies or stained using a human Treg kit (BioLegend). In some experiments, cells were also stained using the above-mentioned CD69, granzyme B, or perforin specific antibodies.
[0245] Immobilized ALT-803 was used for 1 or 4 days ( Figure 5A), resulting in increased IFN-γ release from human PBMCs. Soluble IL-6 was also increased in 4-day cultures of human PBMCs treated with ALT-803, but this effect was not dose-dependent ( Figure 5A In contrast, ALT-803 had no effect on TNF-α, IL-4, IL-10, or IL-17A release from 4-day cultures of human PBMCs. When tested in parallel cultures, the positive control anti-CD3 mAb induced release of IFN-γ, TNF-α, IL-10, IL-4, and IL-17A. Compared to human immune cells, murine splenocytes exhibited similar but less potent IFN-γ release after incubation with ALT-803 ( Figure 5B ). ALT-803 also induced TNF-α production from murine splenocytes, but showed no significant limiting effect on IL-6, IL-2, IL-10, IL-4, and IL-17A. In contrast, murine lymphocytes incubated with immobilized anti-CD3 antibodies showed a significant increase in the release of all cytokines tested. Together, these findings suggest that ALT-803 primarily stimulates IFN-γ production by human and murine immune cells, in contrast to the broad profile of cytokines induced by anti-CD3 antibodies.
[0246] ALT-803 was also evaluated for its ability to induce CellTrace TM The ability of purple-labeled human and mouse immune cells to proliferate. After incubation with 0.7nM to 44nM soluble ALT-803, mouse lymphocytes can be judged to proliferate significantly ( Figure 5C ). In the high-dose soluble ALT-803 group, up to 83% of cells underwent 1 to 6 cell division cycles during the 4-day incubation period. Little or no proliferation was detected in untreated murine cells or those treated with 0.07nM soluble ALT-803. As expected, murine lymphocytes incubated with immobilized anti-CD3 antibodies exhibited a strong proliferative response. ALT-803 dose-dependent lymphocyte proliferation was also observed in human PBMC cultures, but this response was quite small compared to that seen in murine cells. In summary, less than 20% of all human lymphocytes proliferated in response to high-dose ALT-803 and these responses were less than those induced by the positive control anti-CD3 antibody. In addition, independent changes in cell proliferation responses to both ALT-803 and anti-CD3 Ab were observed in blood lymphocytes from different donors.
[0247] Example 2: Induction of cell-mediated cytotoxicity by ALT-803 and ALT-803 in combination with antibodies
[0248] Human PBMCs isolated from buffy coats were used as effector cells to assess whether ALT-803 affects cell-mediated cytotoxicity. Daudi human B-cell lymphoma cells and K562 human myeloid leukemia cells were used as target cells and labeled with Celltrace violet at 5 μM in RPMI-10 at 37°C for 20 minutes as described by the manufacturer. The effector cells were mixed with violet-labeled target cells and incubated at 37°C with 5% CO 2 Incubate for the indicated time in RPMI-10 with or without ALT-803. In some experiments, anti-CD20 Ab (Rituximab, 10 nM), specific for CD20 expressed on the surface of Daudi cells, was added to the effector:Daudi cell cultures to determine the effect of ALT-803 on antibody-dependent cellular cytotoxicity (ADCC) mediated by anti-CD20 Ab. The mixture of effector and target cells was harvested by centrifugation and resuspended in RPMI-10 without phenol red and with 2 μg / ml propidium iodide. The cytotoxicity of effector cells against target cells was evaluated using a flow cytometer by measuring dead purple-labeled target cells after positive staining with propidium iodide.
[0249] like FIG. 6A to FIG. 6D As shown, fresh human PBMCs have weak cytotoxicity against Daudi cells and K562 cells in the absence of ALT-803. In contrast, PBMCs are very strong cytotoxic against Daudi and K562 tumor target cells in the presence of 10 nM ALT-803. Daudi tumor cells express CD20 molecules, which can be recognized by anti-CD20 Ab (Rituximab). As indicated herein, CD20 is an established target for therapeutic antibody treatment of hematological tumors and autoimmune diseases. Human PBMCs can lyse Daudi cells by ADCC means mediated only by Rituximab ( Figure 6C Interestingly, ALT-803 also significantly amplified Rituximab-mediated ADCC activity of human PBMC against Daudi cells. Fig.6D As shown, increasing ALT-803 mediated effects on PBMC cytotoxicity and ADCC were observed over time, with minimal or no response seen after one day of ALT-803 incubation, and increased target cell killing observed with each additional day of incubation.
[0250] In addition, the concentration-dependent induction of ALT-803 against K562 and Daudi cells by human PBMC cytotoxicity was investigated. Fresh human PBMCs were mixed with Celltrace purple-labeled K562 cells or Daudi cells in RPMI-10 medium with various concentrations of ALT-803 (from 0.01 nM to 10 nM) and incubated for 3 days. The cytotoxicity of human PBMCs against target cells was assessed using a flow cytometer as described above. FIG. 6A to FIG. 6D Consistent with the results in the literature, ALT-803 was able to amplify the cytotoxicity of 10 nM human PBMC against Daudi and K562 cells ( Fig. 7A and Figure 7B : donor A and donor B). In addition, it was also demonstrated that ALT-803 as low as 0.01 nM increased the cytotoxicity of human PBMCs against target cells. PBMCs from two individuals exhibited significantly different cytotoxic activities against different tumor target cells. Fig. 7A ) exhibited much higher baseline and ALT-803-induced cytotoxicity against K562 cells than that seen against Daudi cells. In contrast, PBMCs from donor B ( Figure 7B ) exhibited similar baseline and ALT-803-induced cytotoxicity against two different target cells. This finding is important for understanding the potential variability of ALT-803-mediated clinical responses in different patients. Similar cytotoxicity assays will be incorporated as a putative assessment of a patient's immune response to ALT-803 as part of the clinical application of this molecule.
[0251] The concentration-dependent effect of ALT-803 on tumor-specific ADCC was further evaluated. FIG. 8A to FIG. 8B As shown, ALT-803 at concentrations as low as 0.01 nM was able to amplify the ADCC activity of an anti-CD20 mAb (10 nM) against human Daudi B lymphoma cells. This response was observed using human PBMC effector cells incubated with Daudi cells at an E:T ratio of 2:1, demonstrating the sensitivity of this activity. To identify the immune effectors responsible for the observed killing of target tumor cells, NK cells were isolated from human PBMCs by MACS and used as effector cells in the above ADCC assay. Similar to the results using total human PBMCs, NK cells were able to kill Daudi cells via Rituximab-mediated ADCC activity, and this effect was enhanced by the addition of ALT-803 ( Figure 8C ). In contrast, in this setting, NK cell-depleted PBMCs (non-NK cells) did not show ADCC activity in the Daudi cell killing assay ( Fig.8D). In addition, the addition of control antibody HOAT (humanized anti-human tissue factor IgG1 Ab) to NK cells did not provide detectable ADCC activity against Daudi cells with or without the addition of ALT-803.
[0252] The ADCC activity of ALT-803-expanded mouse immune cells against human Daudi cells was also examined. In this study, SCID mice were inoculated with Daudi cells (10 x 10 per mouse) on day 0 (SD0) of the study. 6 ), and treated with ALT-803 (0.2 mg / kg), Rituximab (10 mg / kg), or ALT-803 (0.2 mg / kg) + Rituximab (10 mg / kg) on SD15 and SD18. The mice were sacrificed 4 days after the second treatment and the spleen cells were obtained. Therefore, the spleen cells may have different activation states as a result of in vivo treatment. Subsequently, the spleen cells were mixed with Daudi target cells at an E:T ratio of 20:1 in RPMI-10 medium or in medium with Rituximab (10 nM), ALT-803 (10 nM), or Rituximab (10 nM) + ALT-803 (10 nM). After incubation at 37°C for 2 days, the viability of Daudi target cells was evaluated by propidium iodide staining analysis of purple-labeled Daudi cells on a BD FACSVerse. Fig. 9A As shown, the addition of ALT-803 to splenocytes from control treated mice was able to amplify the anti-CD20 mAb-directed ADCC against human Daudi cells. Furthermore, in vivo stimulation with ALT-803 resulted in splenocytes being more active in anti-CD20 mAb-directed ADCC against human Daudi cells. These results are consistent with those obtained using human immune cells, indicating that ALT-803 treatment can enhance tumor-specific ADCC responses.
[0253] The ADCC activity of ALT-803-expanded immune cells against human tumor cells was examined. HER-2 is an established target for therapeutic antibody treatment of solid tumors, including breast cancer and gastric or gastroesophageal junction adenocarcinoma. To evaluate the ADCC activity of ALT-803 against HER-2 positive tumors, the SK-BR-3 human breast cancer cell line overexpressing HER-2 was used as the target cell line, and anti-human HER-2 antibody (clone 24D2) was used as the Ab targeting tumor cells. To generate activated effector cells, Balb / c mice were injected intravenously with 0.2 mg / kg ALT-803 on day 0 of the study (SD). On SD3, mice were sacrificed and spleens were harvested. Activated splenocytes were mixed with CellTrace purple-labeled SK-BR-3 cells at an E:T ratio of 10:1. Cells were co-cultured at 37°C in R10 medium containing various concentrations of anti-HER2 antibody (clone 24D2), ALT-803, or both agents. After 24 hours, the cell mixture was collected and dead cells were stained with propidium iodide. The percentage of dead SK-BR-3 cells was examined using a flow cytometer. Fig. 9B As shown, incubation of SK-BR-3 cells with activated splenocytes in the presence of anti-HER2 Ab or ALT-803 alone did not result in SK-BR-3 cell death compared to medium control. However, combined treatment with ALT-803 (0.01 to 1.0 nM) and anti-HER2 antibody (clone 24D2) (0.1 to 10 nM) significantly increased ADCC activity of splenic immune cells against SK-BR-3 human breast cancer cells. These results demonstrate that ALT-803 can amplify ADCC responses for several different disease targets identified therapeutically.
[0254] Example 3: Antitumor activity of ALT-803 + tumor-specific antibody therapy in tumor-bearing mice
[0255] ALT-803 was further evaluated in SCID mice bearing Daudi tumors to amplify the anti-tumor activity of anti-CD20 mAbs. These mice have functional NK cells that are likely to mediate ADCC responses against tumors. For this study, FoxChase SCID female mice (Harlan, CB-17 / IcrHsd-Prkdc-scid: 6 weeks old) were inoculated intravenously (iv) with Daudi cells (10 x 10 per mouse). 6(3 mice / group). Fifteen days after tumor inoculation and three days thereafter, tumor-bearing mice were treated with intravenous injection of PBS, ALT-803 (0.2 mg / kg), Rituximab (10 mg / kg), or ALT-803 (0.2 mg / kg) + Rituximab (10 mg / kg). Four days after the second treatment, the mice were sacrificed and the level of Daudi cells in the bone marrow was determined. The percentage of Daudi cells in femoral bone marrow cells was evaluated using a flow cytometer after staining with a PE-conjugated anti-human HLA-DR antibody (Biolegend). Fig.10 The results shown indicate that ALT-803 and anti-CD20 mAb monotherapy can reduce the percentage of Daudi cells in the bone marrow of tumor-bearing mice. However, the combination of ALT-803 plus anti-CD20 mAb provided the greatest anti-tumor activity, reducing bone marrow Daudi cells from 38% in control mice to 5% in mice treated with ALT-803 + Rituximab. Dose response studies in this model confirmed that ALT-803 as low as 0.02 mg / kg was able to amplify the anti-tumor activity of anti-CD20 mAb ( Fig.11 ).
[0256] The ability of ALT-803 plus anti-CD20 mAb to improve the survival of mice bearing Daudi cell tumors was also evaluated. For this study, Fox Chase SCID female mice were inoculated intravenously (iv) with Daudi cells (10 x 10 per mouse). 6 15 days after tumor inoculation and 3 days thereafter, tumor-bearing mice were treated with intravenous injection of PBS, ALT-803 (suboptimal 0.05 mg / kg), Rituximab (10 mg / kg), or ALT-803 (0.05 mg / kg) + Rituximab (10 mg / kg). The survival time of the mice (including the incidence of hind limb paralysis) was monitored. Fig.12 As shown, tumor-bearing mice in the PBS group, suboptimal ALT-803 group, and Rituximab monotherapy group showed a median survival time of 26 to 30 days, while mice treated with suboptimal ALT-803 plus Rituximab had a median survival time of more than 50 days, indicating that the combination therapy significantly prolonged the survival time of mice bearing B-cell lymphoma. At the same time, these results confirmed the synergistic anti-tumor effect of the combination of ALT-803 and tumor-specific antibodies in vivo. It is also worth noting that the combination of ALT-803 plus anti-CD20 mAb did not cause significant signs of toxicity in the tumor-bearing animals used for the above studies, indicating that these combinations are well tolerated.
[0257] Example 4: Antitumor activity of ALT-803 in combination with immune checkpoint blockers in tumor-bearing mice
[0258] Immune checkpoint blockers including antibodies against CTLA-4, PD-1, PD-L1, PD-L2, B7-H3, B7-H4, LAG-3, BTLA, TIM-3, VISTA, IDO, A2aR, HVEM, KIRs, NKG2A, NKG2D, CEACAM-1, 2B4, CD200R, and their ligands, as well as other targets disclosed herein, may promote immune responses by inhibiting immune suppression signals. As described above, ALT-803 is an immunostimulatory molecule that promotes the proliferation and activity of NK cells and T cells. However, its efficacy may be limited by inhibitory checkpoints and pathways that can weaken the immune response. Strategies that abolish these negative regulatory factors and enhance the activity of ALT-803 should provide therapeutic benefits.
[0259] To examine the antitumor activity of ALT-803 in combination with CTLA-4-CD80 / CD86 pathway blockade, a lung metastasis model was developed using BALB / c mice inoculated intravenously with the CT26 murine colorectal cancer cell line. On day 0 (SD0), 2 x 10 5 CT26 tumor cells. In the ALT-803 group, each mouse received 4 μg of ALT-803 intravenously twice a week starting from SD1 for two weeks. Concomitantly with the injection of ALT-803, some mice received anti-PD-L1 antibody (Ab) (clone 9G2), anti-CTLA-4 (clone UC10-4F10-11) Ab, or both, intravenously administered twice a week starting from SD1, with a dosage of 100 μg (each Ab) per injection for two weeks. In the recombinant human IL-15 group, each mouse received 5 μg of IL-15 administered intraperitoneally (ip) once a day and 5 times a week starting from SD1 for two weeks. Concomitantly with the administration of IL-15, animals were also treated with intravenous injections of anti-PD-L1 Ab and anti-CTLA-4 Ab (100 μg per injection) at SD1, SD4, SD8, and SD11. Control mice received injections of PBS. The survival time of mice was evaluated every day as the efficacy endpoint.
[0260] As shown in Figure 13, the median survival time of BALB / c mice bearing CT26 tumors was 15 to 20 days, depending on the study. When compared to the control group, treatment with ALT-803 alone significantly prolonged the survival time of tumor-bearing mice. Adding anti-PD-L1 Ab treatment to ALT-803 did not improve the survival time of these mice. In contrast, the combination of ALT-803 and anti-CTLA4 Ab (with or without anti-PD-L1 Ab) significantly increased the survival time of CT26 tumor-bearing mice compared to the PBS group and the ALT-803 group. Previous studies using this tumor model showed that anti-CTLA4 Ab monotherapy did not improve survival time. Therefore, the combination of ALT-803 and anti-CTLA4 Ab (but not anti-PD-L1 Ab) synergizes in providing a more effective anti-tumor response, as measured by prolonged survival time of tumor-bearing mice.
[0261] The effect of PD-1 blockade or PD-L1 blockade combined with ALT803 was further evaluated in the 5T33P myeloma model in immunocompetent C57BL / 6 mice. At SD0, 1 x 10 7 5T33P tumor cells. Treatment was started on SD4. In the IL-15 group, each mouse received an intravenous injection of 5μg IL-15 on SD4 and SD11. Concomitantly with the injection of IL-15, some animals also received weekly anti-PD-L1 Ab (clone 9G2, 200μg / mouse / intraperitoneal injection) or anti-CTLA-4 Ab (clone UC10-4F10-11, 200μg / mouse / intraperitoneal injection), injected on SD4 and SD11, respectively. In the ALT-803 group, each mouse received two intravenous injections of suboptimal ALT-803 at 1μg / mouse / injection on SD4 and SD11. Concomitantly with the injection of ALT-803, some mice received anti-PD-L1 Ab, anti-CTLA-4 Ab, or both antibodies as described above. In addition, each group of mice received anti-PD-L1 Ab or anti-CTLA-4 Ab monotherapy or PBS injection. The survival time of the mice and / or complete paralysis of both hind limbs were evaluated daily as the study endpoint. Fig.14AAs shown, the median survival time of C57BL / 6 mice bearing 5T33P tumors was 24 days. Treatment with suboptimal doses of ALT-803 did not significantly change the survival time of the animals, but administration of suboptimal ALT-803 plus anti-PD-L1 Ab resulted in a survival time of at least 50 days for all animals in this study group. In contrast, the combination of ALT-803 and anti-CTLA4 Ab did not significantly prolong the survival time of mice. In addition, when suboptimal doses of ALT-803 and anti-PD-L1 Ab were tested as monotherapy and combination therapy, significantly prolonged survival time was observed in C57BL / 6 mice bearing 5T33P tumors after treatment with ALT-803+anti-PD-L1 Ab compared to mice treated with monotherapy ( Fig. 14B ). Thus, the combination of ALT-803 plus anti-PD-L1 Ab provided synergistic antitumor activity in myeloma-bearing mice.
[0262] To better understand the differential activity of ALT-803 combination therapy in these two models, tumor cell lines were stained for ligands of the PD1 and CTLA4 receptors. As shown in Figure 15, CT26 cells express ligands for CTLA4 but not PD1. In contrast, 5T33P tumor cells express PD-L1 but not CTLA4 ligands. These results are consistent with the anti-tumor activity of the combination of anti-CTLA4 and ALT-803 and the combination of anti-PD-L1 Ab and ALT-803 in each of these tumor models, indicating that staining tumors with ligands of immune checkpoint receptors can provide a predictive indication of response to ALT-803 plus immune checkpoint blockade.
[0263] Using the established model for glioblastoma disclosed in Zeng et al. 2013 Int J Radiat Oncol Biol Phys., 86: 343-9, ALT-803 monotherapy and ALT-803 combined with anti-PD-1 mAb were studied in C57BL / 6 mice that had been intracranially transplanted with the glioblastoma cell line GL261-luc. Treatment with multiple doses of ALT-803 (3 or 4 doses) or anti-PD-1 mAb (3 doses) as monotherapy was initiated 7 to 10 days after tumor transplantation, and similar increases in anti-tumor activity and prolonged animal survival were demonstrated when compared to the control group treated with PBS. Combination therapy of ALT-803 with anti-PD1 mAb further prolonged the median survival time of tumor-bearing mice. Furthermore, the percentage of long-term (more than 60 days post-transplant) tumor-free survivors observed in mice treated with anti-PD-1 Ab and ALT-803 monotherapy was 20%, while the combination of anti-PD-1 mAb and 4 doses of ALT-803 increased this value to 40%. Interestingly, the "cured" mice were resistant to re-challenge of the tumor, suggesting that the treatment induced an immune memory response against the tumor. These results suggest that combining the immunostimulatory activity of ALT-803 with the checkpoint blocker anti-PD-1 Ab has a beneficial effect in prolonging the survival of mice bearing glioblastoma.
[0264] It is also noteworthy that the combination of ALT-803 plus checkpoint inhibitor blockade did not cause any significant signs of toxicity in the tumor-bearing animals used in the above studies, indicating that these combinations are well tolerated.
[0265] Example 5: Toxicity of ALT-803 in mice
[0266] To evaluate the safety profile and therapeutic index of ALT-803 in animals and to assess the safety and efficacy of human doses, a toxicity study of multiple doses of ALT-803 treatment was conducted using mice and cynomolgus monkeys. C57BL / 6N mice (10 mice / sex / group) were dosed weekly via the tail vein with 0.1, 1.0 or 4.0 mg / kg of ALT-803 or PBS for 4 weeks. Four days after the last injection (day 26), evaluations including physical examination, blood chemistry, hematology, gross necropsy, body and organ weights, and histopathology were performed (5 mice / sex / group). Similar evaluations were performed on the remaining mice 14 days after the last treatment (day 36). In a second study, C57BL / 6N mice (15 mice / sex / group) were treated with 0.1 or 1.0 mg / kg of ALT-803 or PBS 4 times a week by intravenous injection. The above toxicity evaluation was performed 4 days (day 26) (10 mice / sex / group) or 4 weeks (day 50) (5 mice / sex / group) after the last injection.
[0267] The safety and pharmacodynamics of ALT-803 were evaluated in healthy C57BL / 6N mice that were intravenously injected with 0.1, 1.0 or 4.0 mg / kg of ALT-803 or PBS weekly for 4 consecutive weeks. From 4 to 20 days after the start of treatment, mice receiving 4.0 mg / kg ALT-803 showed signs of toxicity (i.e., weight loss, hair loss) and death. The cause of death was not determined at autopsy, but the observations (i.e., pulmonary edema, spleen enlargement) were consistent with a lethal inflammatory response induced by cytokines. No deaths were observed in mice treated with 1.0 or 0.1 mg / kg ALT-803. Four days after the last dose of ALT-803 (day 26), a dose-dependent increase in spleen tumors and white blood cell (WBC) counts was observed (Figure 16). In WBC, the absolute counts of lymphocytes, neutrophils, and monocytes in mice treated with 1.0 mg / kg ALT-803 were each increased by more than 8 times compared to the control group. Two weeks after treatment (day 36) and four weeks after treatment (day 50) ( FIG. 16A to FIG. 16F ), neutrophil counts in mice treated with 1.0 mg / kg ALT-803 remained elevated, but lymphocyte counts returned to control levels. Histopathological analysis confirmed ALT-803 dose-dependent stimulation of immune cell proliferation and lymphocyte infiltration in spleen, liver, thymus, kidney, lung, and lymph nodes at day 26, reaching lower levels at days 36 and 50. The results of these studies define tolerance to multiple doses of ALT-803 treatment in mice up to 1 mg / kg.
[0268] Example 6: Toxicity, pharmacodynamics (PD), and pharmacokinetics (PK) of ALT-803 in cynomolgus monkeys
[0269] The study was conducted under the provisions of good laboratory practices to evaluate the effects of multiple doses of ALT-803 administered intravenously in cynomolgus monkeys. Animals (5 monkeys / sex / group) were treated weekly with 0.03 or 0.1 mg / kg of ALT-803 or PBS administered intravenously over approximately 3 minutes for 4 weeks (dosing on days 1, 8, 15, and 22). Throughout the survival of the study, the animals were evaluated for clinical and behavioral observations, food intake, body weight, cardiac and eye function. Blood was drawn for hematology, chemistry, and coagulation evaluations (before dosing, and on days 5, 26, and 36 after dosing) and for immune cell analysis. Serum was drawn for immunogenicity testing and PK analysis using a quantitative enzyme-linked immunosorbent assay (ELISA) method. Urine was collected for urinalysis (before dosing, and on days 4, 25, and 35). Clinical pathology tests including physical examination, gross necropsy, organ weight measurement and histopathology were performed 4 days (day 26) (3 animals / sex / group) and 2 weeks (day 36) (2 animals / sex / group) after the last injection.
[0270] Based on analogy with tolerable murine doses, the activity and toxicity of ALT-803 were evaluated in healthy cynomolgus monkeys after multiple intravenous doses of 0.1 and 0.03 mg / kg. PK analysis after the first dose estimated the first elimination half-life of ALT-803 to be approximately 7.6 hours, with no significant differences between dose levels ( Fig.17 ). For 0.1mg / kg ALT-803, C max The value was 30 nM, consistent with complete recovery of the administered dose, while C max and AUC INF The values indicated that the recovery was 30% less at the 0.03 mg / kg dose. However, even at the low dose level, serum C max At 6 nM, it is still 50 times higher than the 0.1 nM concentration found in vitro to stimulate immune cell proliferation, activation and cytotoxicity.
[0271] Monkeys that received weekly injections of ALT-803 for 4 weeks showed a dose-dependent decrease in appetite within 2 weeks of treatment. However, there were no significant differences in mean body weight or any other dose-related clinical or behavioral observations during the study. In addition, organ weights in animals treated with ALT-803 were not significantly different from those in the control group.
[0272] The most biologically relevant changes observed after weekly ALT-803 treatment were dose-dependent increases in blood WBC and lymphocyte counts ( 18A to 18HAt the end of the 4-week dosing period, the absolute lymphocyte counts in animals receiving 0.1 mg / kg ALT-803 increased by 1.5-fold, and then returned to control levels after a 2-week recovery period. Among lymphocyte subsets, transient NK cells and CD4 + and CD8 + Dose-dependent increase in T cell counts ( Figures 18A-18F ). Blood monocyte counts were also increased in monkeys treated with 0.1 mg / kg ALT-803, while blood neutrophil levels did not differ between treatment groups. These results contrast with previous studies of IL-15 administration to rhesus and cynomolgus monkeys, where the main toxicity reported was transient grade 3 / 4 neutropenia.
[0273] Based on histopathological analysis performed 4 days after the last dose of ALT-803, in addition to changes in blood immune cell levels, there was a dose-dependent increase in mild multifocal lymphocytic infiltration in the liver, kidney, and lung of ALT-803-treated monkeys. Scattered mild liver necrosis was also found in animals treated with ALT-803 at increasing dosing frequencies. Clinical chemistry at this time point showed a decrease in serum albumin in the high-dose ALT-803 group compared with the control group (0.1 mg / kg ALT-801, 3.85±0.12 g / dL; PBS, 4.46±0.13 g / dL; P<0.01), which may be a consequence of the inflammatory response in the liver. However, serum liver enzyme levels in ALT-803-treated animals were not elevated compared with controls. Myeloproliferation was observed in most animals, but with increased severity in the high-dose ALT-803 group. The ALT-803-treated group had reduced incidence and severity of major lesions in affected organs after 2 weeks of treatment, consistent with those found in control animals. In general, the ALT-803-mediated effects on blood and tissue lymphocytes observed in this study were consistent with transient responses reported in nonhuman primates treated with IL-15 up to 0.1 mg / kg twice weekly or 10 to 50 μg / kg daily.
[0274] Example 7: Comparative Study of Intravenous and Subcutaneous ALT-803
[0275] Emerging data from ongoing trials using recombinant human IL-15 (rhIL-15) products suggest that intravenous administration may not be optimal for IL-15 because it induces high C maxand secondary cytokine release (IL-6 and IFN-γ), which affects its tolerability and therefore limits its application. Preclinical and clinical studies using IL-2 have shown that subcutaneous administration is safer and provides much better tolerability. For example, Waldmann and colleagues conducted the first solid tumor trial of rhIL-15 in humans, with daily intravenous push for 12 consecutive days (Conlon et al., 2015. J. Clin. Oncol., 33: 74-82). The dose-limiting toxicities observed in the 3.0 and 1.0 μg / kg daily groups were grade 3 hypotension, thrombocytopenia, and elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The stated maximum tolerated dose (MTD) is 0.3 μg / kg per day. The increased tolerance of subcutaneous administration is C max The expected result is a reduction in circulating rIL-15 product levels compared to the same level of intravenous administration. max Allowing for more drug to be delivered overall.
[0276] To extend these findings to ALT-803, preclinical studies in C57BL / 6 mice were performed to evaluate iv (intravenous) and sc (subcutaneous) administration of ALT-803 in terms of pharmacokinetics, immunostimulation, and anti-tumor efficacy. Preliminary studies in C57BL / 6 mice treated with 0.2 mg / kg ALT-801 showed an estimated half-life of 5.3 hours for intravenous administration and 3.8 hours for subcutaneous administration. The maximum serum concentration and time point of ALT-803 were 650 ng / ml at 20 hours after subcutaneous administration and 1700 ng / ml at 2 hours after intravenous administration. From an immunostimulatory standpoint, subcutaneous or intravenous administration of ALT-803 induced CD8 + Proliferation of T cells and NK cells. In addition, intravenous and subcutaneous administration of ALT-803 also activated immune cells to reduce the tumor burden in the bone marrow of mice bearing 5T33 myeloma. Both intravenous and subcutaneous administration of ALT-803 up to 0.2 mg / kg was well tolerated in normal and tumor-bearing C57BL / 6 mice.
[0277] Follow-up studies of toxic effects in C57BL / 6 mice treated with 1 mg / kg ALT-803 subcutaneously weekly for 4 weeks showed immune system-related changes similar to those seen in previous toxicology studies in which the same ALT-803 dosing regimen and intravenous route were used. No deaths were observed in mice treated with 1 mg / kg ALT-803 subcutaneously weekly for 4 consecutive weeks. No clinical signs of toxicity related to the test items were observed during this study, except for slight weight loss and a general hunched posture after the first subcutaneous injection of ALT-803. Peripheral blood examinations showed an increase in WBC and lymphocyte counts compared to the PBS control group. Overall, animals treated with ALT-803 had a 9-fold increase in both WBC and lymphocytes compared to PBS-treated mice. Increases in neutrophils, monocytes, eosinophils, and basophils were also observed in mice treated with subcutaneous injections of ALT-803. Significant increases in spleen, lymph node, and liver weights were observed in mice treated with ALT-803 (5.5-fold, 3-fold, and 1.3-fold, respectively). It has been previously reported that mice treated with multiple doses of ALT-803 intravenously have fairly extensive enlargement of immune cells and increased weights of lymphoid organs.
[0278] In summary, the results of preclinical studies of ALT-803 showed that subcutaneous administration reduced C max , but maintains immunostimulatory activity and antitumor efficacy without increasing toxicity.
[0279] Example 8: Antitumor activity of ALT-803 combined with immune checkpoint blockers in mice bearing orthotopic bladder tumors
[0280] In addition to the studies disclosed in Example 4, the antitumor activity of ALT-803 in combination with immune checkpoint blockers was evaluated in mice bearing orthotopic MB491uc bladder cancer. On day 0, C57BL / 6 mice (n=6 / group) were inoculated with MB491uc cells (3 x 10 4 The mice were maintained to evaluate the survival between treatment groups as an efficacy endpoint. ALT-803 treatment significantly prolonged the survival of MB491uc-bearing mice (100 μg / injection, ip) compared with the PBS group. Fig.19A). However, the combination of ALT-803 with anti-PD-L1 and anti-CTLA4 Abs further prolonged survival compared with the monotherapy control group. This effect was also seen in the combination therapy of ALT-803+anti-PD1 and ALT-803+anti-PD1 / anti-CTLA4 mAbs ( Fig.19B ).
[0281] Furthermore, mice cured of their tumors by ALT-803 plus anti-PD-L1 / anti-CTLA4 Ab therapy were resistant to rechallenge with bladder tumors and did not require further drug treatment, whereas age-matched untreated mice developed tumors and died after tumor cell inoculation ( Fig.19A ). These results indicate that ALT-803 monotherapy and its combination with anti-PD-L1, anti-PD-1, and anti-CTLA4 Abs are effective in treating mice with bladder tumors, including curative responses; and that the ALT-803 / anti-PD-L1 / anti-CTLA4 Ab combination therapy provides immune memory responses to subsequent tumor challenges. It is also noteworthy that the combination of ALT-803 plus checkpoint inhibitor blockade did not cause significant signs of toxicity in the tumor-bearing animals used in the above studies, suggesting that these combinations are well tolerated. Fig. 20 As shown, MB491uc cells express ligands for CTLA4 and PD-1. If so, these results are consistent with the antitumor activity of the combination of anti-CTLA4, anti-PD-1, and anti-PD-L1 Abs with ALT-803 in this tumor model.
[0282] Example 9: Combination therapy of ALT-803 and anti-gp75 antibody TA99 in a murine melanoma model
[0283] The efficacy of ALT-803 plus therapeutic tumor antigen-specific antibodies against solid tumors was further evaluated using a subcutaneous B16F10 melanoma tumor model in syngeneic C57BL / 6 mice. This model also has the advantage of evaluating the activity of T cells and other immune cells against established tumors and tumor rechallenge. An important melanoma-specific antigen for targeted therapy is gp75 (TYRP-1, tyrosinase-related protein 1), a 75 kDa protein involved in melanin synthesis in melanosomes (Kobayashi T, et al. 1994. EMBO J. 13: 5818-25). TA99 (murine IgG2a) is a monoclonal antibody (mAb) specific for human and murine gp75 (Thomson TM, et al. 1985. J Invest Dermatol. 85: 169-74). Treatment with this antibody effectively abolished subcutaneous murine B16F10 melanoma in syngeneic mice via antibody-dependent cellular cytotoxicity (ADCC) (Hara I, et al. 1995. J Exp Med. 182: 1609-14).
[0284] The experiments disclosed herein were designed to determine whether this activity could be further amplified by combination with ALT-803 and to evaluate the immune response as a cause of anti-tumor efficacy. Typically, on day 0 (SD0), C57BL / 6NHsd mice (7 weeks old, female) were injected subcutaneously in the lower dorsal flank with 2 x 10 5B16F10 tumor cells. For all experiments in this study except for tumor re-challenge, treatment was given twice a week starting from SD10 for two weeks (dosing on days 10, 14, 17, 21 and 24 of the study), and the dosing time point was when more than 75% of the animals had palpable B16F10 tumors. More specifically, mice were divided into several groups and injected with 200 μL PBS (iv) (vehicle control), 0.2 mg / kg ALT-803 (iv), 10 mg / kg TA99 (iv), 100 μg / mouse of anti-PD-L1 mAb 10F.9G2 (ip), or a combination of ALT-803, TA99 and / or 10F.9G2. For depletion experiments, 200 μg / mouse depletion antibodies (anti-CD4 GK1.5, anti-CD8a 53.6.72, and anti-NK1.1 PK136) were injected intraperitoneally once a week starting from SD3 and SD9, respectively, or 100 μL / mouse Clophosome (liposomes loaded with clodronate for depletion of macrophages) were injected intraperitoneally every four days. For experiments involving eventual re-challenge, 10 mg / kg TA99 (iv) was administered three times a week starting from SD0, and 0.2 mg / kg ALT-803 (iv) was administered once a week for three weeks. About three months later, tumor-free mice that survived the initial tumor challenge were injected subcutaneously with 2 x 10 in 200 μL PBS on the contralateral side of the body. 5 B16F10 tumor cells. From the first day of treatment until the end, the volume of the tumor was measured every day and the formula 1 / 2 (length x width) was used. 2 ) were calculated. Mice bearing tumors with one dimension >20 mm were considered dead. Mice without palpable tumors or subcutaneous tumors with a volume less than 50 mm were considered dead. 3 Mice were considered tumor-free.
[0285] In a preliminary study, mice (n=8) bearing established tumors were treated twice weekly for two weeks with TA99, ALT-803, TA99+ALT-803, or PBS control. Fig.21A Due to delayed therapeutic intervention, no tumor regression was observed in any treatment group. However, tumor progression was significantly inhibited by TA99 (p < 0.001) and ALT-803 (p < 0.001) compared with the PBS treatment group. The combination therapy resulted in a significant increase in the inhibition of tumor growth compared with monotherapy (p < 0.001), indicating that ALT-803 provides additional protection to the antibody-dependent immunity against tumors.
[0286] To determine which immune cell subsets are responsible for ALT-803 / TA99-mediated anti-melanoma immunity, T lymphocytes, NK cells, and macrophages were depleted prior to or throughout the course of treatment by intraperitoneal administration of cell type-specific antibodies or liposomes. + Depletion of T cells, NK cells, and macrophages significantly reduced the inhibition of tumor growth by the combination therapy (p < 0.001; Fig. 21B ), indicating that all three cell subsets contribute to the efficacy of ALT-803 and TA99.
[0287] Surprisingly, compared with the non-depleted ALT-803+TA99 treated group, CD4 + Depletion of T cells not only resulted in a significant improvement in tumor suppression (p < 0.001; Fig. 21B ), and caused a significant increase in animal survival time (p < 0.01; Fig. 21C ). Considering CD4 + T cells are critically involved in immune regulation, and this finding suggests that these cells (or CD4 + The results showed that the subset of T cells played an immune suppressive rather than an immune activating role in ALT-803 / TA99-mediated immunity against B16F10 tumors.
[0288] The effects of treatment on immune cells in spleen cells and tumor-infiltrating leukocytes (TILs) from mice bearing B16F10 melanoma tumors 3 days after treatment were examined. + Increased T cell and NK cell populations, as well as CD4 + Decreased T cell, B cell, and macrophage populations ( Fig.22A and Fig. 22B ). As expected, TA99 did not alter the percentage of immune cell subsets in splenocytes or TILs, but caused a small reduction in tumor-associated macrophages. The ALT-803 / TA99 combination showed similar changes in immune cell populations as ALT-803 alone. ALT-803 alone or in combination with TA99 resulted in a decrease in CD8 + T cell memory phenotype (CD44 高 ), supported by data from splenocytes and TILs ( Fig. 22C and Fig.22D ). Due to the baseline CD8 + CD44 高 The T cell population was twice as high as that in the spleen, and memory CD8 +ALT-803-mediated expansion of T cells was not significant (1.2-fold, p < 0.01; and 2.5-fold in spleen, p < 0.001). TA99 slightly reduced the expression of memory CD8 TILs. + The percentage of T cells (p < 0.05) may be due to more effector CD8 + T cells are driven to join antibody-dependent immunity against melanoma.
[0289] To evaluate whether the immune memory enhanced by ALT-803 would contribute to improved long-term immunity against tumor cells, ALT-803+TA99 treatment was initiated on day 0 in mice challenged with B16F10 tumors in an attempt to cure. In this treatment regimen, the addition of ALT-803 to TA99 therapy did not provide an improvement in animal survival time, but a modest increase in the percentage of tumor-free animals was observed at SD60 ( Fig.23A However, when surviving mice from the ALT-803+TA99 group were re-challenged with B16F10 cells, a significant delay in tumor development was observed compared with age-matched but untreated mice ( Fig. 23B ). These findings support the hypothesis that prior ALT-803 treatment induces an immune cell response that is critical for "vaccine" protection of animals subjected to subsequent tumor re-challenge. To evaluate which cells are involved in this protective effect, a depletion study of ALT-803+TA99 "cured" mice was performed prior to tumor cell re-challenge. The results showed that ALT-803+TA99 "cured" mice administered PBS remained protected from B16F10 tumor re-challenge; whereas those "cured" mice treated with antibodies that depleted CD8, CD4, or NK cells showed no immune protection against death from subcutaneous B16F10 tumor re-challenge ( Fig.23C ). These results indicate that these cell types are all involved in the protective effect mediated by ALT-803+TA99 treatment after initial tumor inoculation.
[0290] The role of immune cell activation and the PD-1 / PD-L1 axis in this model was also evaluated. A single dose of ALT-803 upregulated tumor infiltrating CD4 + CD25 in T cells + cells (p < 0.05), while TA99 downregulated this activation marker (p < 0.01; Fig.24A ). In addition, ALT-803 treatment significantly increased peripheral (p < 0.001; Fig. 24B ) and within tumors (p < 0.01; Fig.24C ) + PD-L1 expression on T cells. TA99 treatment only resulted in the expression of CD4 +The slight reduction in PD-L1 expression on T cells (p < 0.05) with TA99 and ALT-803 was not sufficient to alter the effect from ALT-803 alone. Therefore, the effectiveness of ALT-803 and its combination with therapeutic antibodies will likely be limited to the CD4+ T cells. + Immune checkpoint inhibitor pathways for T cell potentiation.
[0291] The effects of ALT-803 on CD8 + Effect of PD-1 expression on T cells. A single dose of ALT-803 resulted in a decrease in splenic CD8 + A modest reduction in PD-1 expression on T cells restored it to levels close to those of naive mice ( Fig.24C In addition, ALT-803, TA99, and the combination of ALT-803+TA99 all reduced tumor-infiltrating CD8 + PD-1 expression on T cells decreased by approximately 3-fold ( Fig.24D ).
[0292] An important anti-tumor mechanism of IL-15 is through the activation of NK cells. When the activation marker KLRG1 on NK was examined, it was found that B16F10 melanoma, despite its extremely poor ability to generate immunity, could induce a modest increase in KLRG1 on spleen NK cells (p < 0.05; Fig.25A ). ALT-803 treatment further increased NK cell activation in the spleen (p < 0.05; Fig.25A ), and more importantly, it caused a substantial increase in KLRG1 expression on tumor-infiltrating NK cells (4-fold, p < 0.001; Fig.25B This may explain why ALT-803 can effectively promote TA99-mediated ADCC against B16F10 tumors, in which NK cells are the main immune cells involved in this response. + Similar to T cells, ALT-803 also downregulated spleen (p < 0.01; Fig.25C ) and tumors (p < 0.05; Fig.25D ) on NK cells, suggesting that ALT-803 can intrinsically attenuate + Inhibition of the PD-1 arm of the checkpoint pathway on T cells and NK cells, independent of additional checkpoint blockade.
[0293] To explore whether checkpoint blockade would further enhance the combined anti-tumor function of ALT-803 and TA99, mice bearing established B16F10 tumors (n=8) were treated with ALT-803+TA99 with or without anti-PD-L1 mAb 10F.9G2 in a delayed intervention model ( Fig.26A ). Anti-PD-L1 mAb alone slowed tumor growth by a small factor (p < 0.05). Fig.26B ), but anti-PD-L1 mAb failed as a potential monotherapy for inhibiting melanoma growth in this model. Judging from the tumor growth curve, the combination of ALT-803+TA99 and anti-PD-L1 mAb did show higher anti-tumor activity than ALT-803+TA99 therapy (p<0.05).
[0294] Overall, the results of these studies indicate that ALT-803 in combination with a tumor-specific antibody can provide anti-tumor activity and prolong the survival of mice bearing established solid tumors. This treatment also provides immune protection against further tumor re-challenge. These effects are mediated by NK cells and T cells, which are activated and proliferate in response to treatment. In addition, combination with therapeutic amounts of checkpoint inhibitors can further expand the anti-tumor efficacy of this ALT-803 + tumor-specific antibody regimen. As a result, ALT-803 monotherapy and ALT-803 combination therapy strategies can be used in a variety of therapeutic approaches for the treatment of neoplasia, including adjuvant therapy, neoadjuvant therapy, induction therapy, consolidation therapy, maintenance therapy, first-line therapy, ≥ second-line therapy, and in combination with surgery, radiotherapy or chemotherapy.
[0295] It should also be noted that ALT-803 alone or in combination with anti-tumor antibodies and / or checkpoint inhibitor blockade did not cause any significant signs of toxicity in the tumor-bearing animals used in the above studies, suggesting that these combinations are well tolerated.
[0296] Example 10: Clinical study of ALT-803 in patients with malignant tumors
[0297] ALT-803 was evaluated in patients with malignant tumors as described below.
[0298] A multicenter clinical study of ALT-803 was conducted in patients with malignant melanoma and other solid tumors. The study was conducted by recording individual dose escalation for each patient in the first two cohorts and a minimum of three patients in the last three cohorts to determine the maximum tolerated dose (MTD) or optimal biological dose (OBD) of ALT-803. Enrolled patients received two 6-week cycles, each consisting of 4 weeks of weekly intravenous administration of ALT-803 followed by a 2-week rest period.
[0299] Patients with stable or improving disease are eligible to receive up to two additional 6-week cycles. One patient received the 0.3 μg / kg ALT-803 dose level. Drug-emergent adverse reactions reported were transient low-intensity fever, chills, nausea, and vomiting. The next patient received the 0.5 μg / kg dose level. Adverse reactions reported were all mild to moderate and included nausea, fatigue, and pruritus. Three patients participated in and completed the study treated at the 1 μg / kg ALT-803 dose level. Adverse reactions reported in these patients were all mild to moderate and included chills, persistently worsening constipation, and hypertension. The study protocol for this trial was amended to renal cell carcinoma, non-small cell lung cancer, and squamous cell head and neck cancer. Three patients, including one with renal cell carcinoma, received the 3 μg / kg dose level. Adverse reactions reported to date are mild to moderate and include fever, fatigue, vomiting, and myalgia. No dose-limiting toxicity, grade 3 / 4 toxicity, or serious adverse events were observed in any of the patients treated with ALT-903, indicating that this treatment was well tolerated. Disease stabilization has been reported in some patients, and treatment-mediated clinical benefits (including reductions in tumor burden, disease progression or recurrence, or toxicity, or increases in progression-free survival, time to progression, durability of response, survival, or quality of life) are expected.
[0300] A multicenter clinical study of ALT-803 was conducted in patients with hematological malignancies who relapsed after autologous stem cell transplantation (ASCT). The first phase of this study conducted toxicity studies under a standard dose-escalation 3+3 design. Participating patients received intravenous administration of ALT-803 once a week for 4 weeks. Six patients participated in and completed the study at a dose level of 1 μg / kg ALT-803. For the first three patients, the adverse reactions reported by the study drug were fever, chills, shivering, and edema. Two patients had a grade 1 fever approximately 4 to 5 hours after administration of ALT-803, which then subsided 6 to 7 hours after administration of ALT-803. Two patients had a grade 2 chill, two patients had a grade 2 chill, and one patient had a grade 1 chill. One patient with a grade 2 chill required pethidine at 3 of the 4 ALT-803 doses. One patient experienced grade 2 edema, and another patient experienced grade 1 edema. The first three patients experienced asymptomatic hypotension, but these patients recovered to normal after the administration of fluids without recurrence of hypotension. None of the treated patients were pre-hydrated. One patient was also observed to have grade 2 pruritus after the second dose of ALT-803, which was consistent with graft-versus-host disease. The fourth, fifth and sixth patients received the study treatment without adverse reactions. Three patients completed the study with treatment at the 3μg / kg ALT-803 dose level. These patients received rehydration before each dose, and the adverse reactions reported included grade 1 fever and chills 6 to 10 hours after the administration of ALT-803. Three patients participated in and completed the study with treatment at the 6μg / kg ALT-803 dose level. The most commonly reported adverse reactions in this group included mild to moderate fever, chills and flu-like symptoms. Two patients were treated at the 10μg / kg ALT-803 dose level. Adverse reactions reported by the first patient after administration of ALT-803 included transient fever, nausea and vomiting. Adverse reactions began about 3 hours after administration and lasted for about 4 hours. The patient also experienced low-intensity asymptomatic hypotension. Blood pressure returned to baseline with intravenous fluids. The second patient experienced transient fever and chills after the first dose of ALT-803. Chills were controlled with pethidine. No dose-limiting toxicity, grade 3 / 4 toxicity, or serious adverse reactions were seen in any of these patients treated with ALT-903, indicating that this treatment was well tolerated. The draft was revised to change the administration of ALT-803 from intravenous injection to subcutaneous injection starting at a dose level of 6μg / kg. Patient participation will continue at the intravenous 10μg / kg dose level until all three patients are included in this group. Patients then began participating in subcutaneous injections of 6μg / kg. Treatment-mediated clinical benefits (including reductions in tumor burden, disease progression or recurrence, or toxicity, or increases in progression-free survival, time to progression, durability of response, survival time, or quality of life) are expected.
[0301] Clinical biomarker evaluation. For patients with malignant hemophilia after ASCT, the NK, CD4 + 、CD8 + Initial data were obtained by Ki-67 analysis of NKT cell subsets and serum cytokines. Serum levels of both IFN-γ and IL-6 were induced in a dose-dependent manner over the dose range from 1 μg / kg to 6 μg / kg ALT-803. Ki67 was elevated in all patients after administration of ALT-803 at dose levels ≥3 μg / kg. + NK、CD8 + and CD4 + Thus, initial data suggest that for this indication, ALT-803 consistently promotes activation and proliferation of NK, T, and NKT cells in patients dosed at ≥3 μg / kg. Similarly, serum levels of IFN-γ and IL-6 were induced in patients with solid tumors following administration of ALT-803, suggesting treatment-related immune stimulation in these patients.
[0302] A multicenter clinical study of ALT-803 was conducted in patients with relapsed or refractory multiple myeloma. The first phase of the study included a classic (3+3) dose escalation to determine the MTD or minimum effective dose (MED) and to designate dose levels for Phase II two-stage expansion. The dose levels are 1, 3, 6, 10 and 20 μg / kg of ALT-803. Participating patients will receive two 6-week cycles, each consisting of 4 weeks of weekly intravenous administration of ALT-803 and a 2-week rest period thereafter. Patients with stable or improving disease are eligible for up to two additional 6-week cycles. Three patients participated in and completed the study treated at a dose level of 1 μg / kg ALT-803. All adverse reactions reported were mild to moderate, including constipation, nausea, fatigue, decreased ALC, and decreased WBC counts. All patients received preoperative medication. Two patients were treated at a dose level of 3 μg / kg ALT-803. Adverse reactions reported included mild to moderate fever, chills, and neutropenia. No dose-limiting unique, grade 3 / 4 toxicities or serious adverse reactions were observed in any patient treated with ALT-903, indicating that this treatment was well tolerated. Treatment-mediated clinical benefits (including reductions in tumor burden, disease progression or recurrence, or toxicity, or increases in progression-free survival, time to progression, durability of response, survival, or quality of life) are expected. Serum levels of IFN-γ and IL-6 were induced in patients with multiple myeloma following administration of ALT-803, indicating treatment-related immune stimulation in these patients.
[0303] A multicenter clinical study of the combination of ALT-803 and Bacillus Calmette-Guerin (BCG) was conducted in patients with non-muscle invasive bladder cancer who had not been treated with BCG. The first phase of this study included a classic (3+3) dose escalation to determine the MTD of ALT-803 and the recommended dose (RD) of the combination of ALT-803 and BCG for the expansion phase. The dose levels were 100, 200 and 400 μg / instillation of ALT-803 plus standard BCG (50 mg / instillation). The expansion phase consisted of a non-comparative randomized design of patients receiving RD levels of ALT-803 with BCG alone or in combination with BCG. Participating patients will receive BCG plus ALT-803 in the bladder via a catheter every week for 6 weeks. Three patients participated in and completed treatment of the first population with 100 μg / instillation of ALT-803. Reported adverse reactions caused by the study drug included moderate malignancy, headache, hematuria and urinary tract pain, as well as mild non-infectious cystitis. Three patients participated and completed treatment with 200 μg / drip of ALT-803 plus BCG. Adverse reactions reported for the study drug included moderate hematuria and urinary incontinence. Two patients participated as a group treated with 400 μg / drip of ALT-803. No dose-limiting toxicity, grade 3 / 4 toxicity, or serious adverse reactions were observed in these patients treated with ALT-903 plus BCG, indicating that this treatment was well tolerated. Most of these treated patients showed no disease recurrence for at least 9 months after treatment (considered a complete response in this indication), indicating treatment-related clinical activity. In some patients, treatment-related increases in urinary cytokines were also observed. Treatment-mediated clinical benefits (including reductions in tumor burden, disease progression or recurrence, or toxicity, or increases in progression-free survival, time to progression, durability of response, survival time, or quality of life) are expected.
[0304] A multicenter clinical study of ALT-803 plus rituximab is being conducted in patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma. The first phase of the study includes a classic (3+3) dose escalation to determine the MTD or MED and to specify the dose level for the two-stage expansion of Phase II. The dose levels are 1, 3 and 6 μg / kg of ALT-803. Participating patients will receive a 4-week induction cycle consisting of weekly intravenous administration of ALT-803 and standard rituximab (375 mg / m 2). Patients with stable or improving disease will receive up to 4 cycles of consolidation therapy, each cycle being a single course of ALT-803 plus rituximab, repeated every 8 weeks, for a total of 4 additional doses of ALT-803 and rituximab. One patient is enrolled and is currently receiving treatment at a dose level of 1 μg / kg ALT-803. Therefore, the adverse reactions reported so far for this patient are mild to moderate and include edema, decreased ALC, and decreased WBC counts. No dose-limiting toxicity, grade 3 / 4 toxicity, or serious adverse reactions were observed in patients treated with ALT-903+rituximab, indicating that this treatment is well tolerated. Treatment-mediated clinical benefits (including reduction of tumor burden, disease progression or recurrence, or toxicity, or increase in progression-free survival, time to progression, durability of response, survival time, or quality of life) are expected.
[0305] A multicenter clinical study of ALT-803 plus nivolumab (anti-PD-1 Ab) will be conducted in patients with advanced or metastatic non-small cell lung cancer. The first phase of the study includes dose escalation to determine the MTD of ALT-803 and specify the dose level for Phase II two-stage expansion. The dose level is 6, 10, and 15 μg / kg of subcutaneous ALT-803. Participating patients will receive two 6-week cycles, each consisting of 5 weeks of weekly administration of ALT-803 and standard nivolumab (3 mg / kg) administered intravenously every two weeks. Patients with stable or improving disease will receive an additional 6-week cycle of ALT-803 plus nivolumab. Treatment-mediated clinical benefits (including reduction of tumor burden, disease progression or recurrence, or toxicity, or increase in progression-free survival, progression time, response durability, survival time, or quality of life) are expected.
[0306] Other specific embodiments
[0307] While the invention has been disclosed in conjunction with the detailed description thereof, the foregoing description is intended to illustrate rather than limit the scope of the invention, which is defined by the scope of the claims. Other aspects, advantages and modifications are within the scope of the claims.
[0308] The patents and scientific literature referred to herein constitute the knowledge available to those skilled in the art. All U.S. patents and published or unpublished U.S. patent applications cited herein are incorporated herein by reference. All published foreign patents and patent applications cited herein are incorporated herein by reference. The Genbank and NCBI deposits represented by the accession numbers cited herein are incorporated herein by reference. All other published references, documents, manuscripts and scientific literature cited herein are incorporated herein by reference.
[0309] While the invention has been particularly shown and described with reference to preferred specific embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention as encompassed by the claims.
Claims
1. A combination of an antibody and a pharmaceutical composition, the pharmaceutical composition comprising IL-15N72D:IL-15RαSu / Fc complex ALT-803, Wherein the ALT-803 is composed of a dimer IL-15RαSu / Fc and two IL-15N72D molecules; The IL-15N72D molecule is shown in SEQ ID NO: 3; wherein the IL-15RαSu / Fc is represented by SEQ ID NO:6; and The antibody is an anti-PD-1 antibody or an anti-PDL1 antibody.
2. The combination according to claim 1, wherein the anti-PD-1 antibody is selected from nivolumab, pembrolizumab, pidilizumab, TSR-042, ANB011, AMP-514 and AMP-224.
3. The combination according to claim 2, wherein the anti-PD-1 antibody is nivolumab.
4. A combination according to any one of claims 1 to 2 for use in medicine.
5. The combination according to claim 3 for use in medicine.
6. Use of the combination according to claim 1 in the preparation of a medicament for treating non-small cell lung cancer in a subject.
7. Use of the combination according to claim 3 in the preparation of a medicament for treating non-small cell lung cancer in a subject.
8. The use according to any one of claims 6 to 7, comprising administering an effective amount of the ALT-803 daily.
9. The use according to claim 8, wherein the effective amount of the ALT-803 is 0.1 μg / kg to 100 mg / kg.
10. The use according to any one of claims 6 to 7, comprising administering an effective amount of the ALT-803 once or twice a week.
11. The use according to claim 10, wherein the effective amount of the ALT-803 is 0.1 μg / kg to 1 mg / kg.
12. The use according to any one of claims 6 to 7, wherein the pharmaceutical composition is administered systemically, intravenously, subcutaneously, intramuscularly, intravesically, or by instillation.
13. The use according to any one of claims 6 to 7, wherein the subject is a human.
14. The use according to any one of claims 6 to 7, wherein the antibody and the ALT-803 are administered simultaneously or sequentially.
Citation Information
Patent Citations
Multimeric il-15 soluble fusion molecules and methods of making and using same
US20140242025A1
Hybrid immunoglobulins
US5116964A
Expression and export technology of proteins as immunofusins
US5541087A
Initiative system
US5620939A
Multimeric IL-15 soluble fusion molecules and methods of making and using same
US8507222B2
